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Abstract
Chemical Reactions: Marijuana, Opioids, and Our Families is the seventh Massachusetts Family Impact Seminar.
This seminar was designed to emphasize a family perspective in policymaking on issues related to the
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 Chemical Reactions:  
Marijuana, Opioids, and Our Families
Purpose and Presenters
 
in 2009, clark university was accepted to represent massachusetts  
in the family impact institute at the university of Wisconsin — madison 
(familyimpactseminars.org), an organization of universities nationwide that 
conduct family impact seminars. in 2014, the family impact institute  
moved its host site to purdue university.
Family Impact Seminars are a series of annual seminars, briefing reports, and discussion sessions that 
provide up-to-date, solution-oriented research on current issues for state legislators and their aides. The 
seminars provide objective, nonpartisan research on current issues and do not lobby for particular policies. 
Seminar participants discuss policy options and identify common ground where it exists.
Chemical Reactions: Marijuana, Opioids, and Our Families is the seventh Massachusetts Family Impact 
Seminar. This seminar was designed to emphasize a family perspective in policymaking on issues related  
to the legalization of marijuana and managing the opioid abuse crisis in the Commonwealth.  In general,  
Family Impact Seminars analyze the consequences an issue, policy, or program may have for families.
tHis seMinaR featuReD tHe following speaKeRs: 
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Introduction
by Denise a. Hines, ph.D.
two major issues relating to drugs have been hitting the headlines recently, 
and massachusetts legislators are working hard to address them. the first 
is the legalization of recreational marijuana use in the commonwealth of 
massachusetts. 
Although medical marijuana use is currently legal, citizens of our state will be faced with a ballot question 
in the November 2016 elections regarding whether to legalize recreational use. Polls show that Massachusetts 
voters are closely divided on the issue, and if they vote for legalization this November, Massachusetts 
legislators will have the monumental task of figuring out how to implement it.
While we are considering legalizing one substance, another substance has caught legislators’ and the 
public’s attention because of its rising rates of abuse, overdoses, and deaths: opioids. As the opioid abuse crisis 
reaches epidemic levels, legislators are working hard to find ways to help addicts and their families avoid or 
recover from addiction.
After consultation with legislators, we decided that our 2016 Massachusetts Family Impact Seminar would 
focus on these two substance use and abuse issues. The title of our seminar in March of 2016 was “Chemical 
Reactions: Marijuana, Opioids, and Our Families,” and we brought in four experts to speak to legislators, their 
staff, public health officials, and other interested parties. 
This briefing report represents a summary of that seminar. It contains the transcripts and slides of the four 
talks from our seminar. It also contains four policy briefs written by each of our experts that were distributed at 
the seminar. 
Our morning session featured two experts on the use and abuse of marijuana, and on policy options 
available to deal with it. Dr. Staci Gruber of McLean Hospital and Harvard Medical School spoke about 
marijuana’s influence on the developing brain. Her take-away message was that marijuana is not harmless 
as it is often thought to be, particularly for adolescents, and therefore, any policies regulating its use needs to 
consider how to keep it out of the hands of young people. Dr. John Kelly of Massachusetts General Hospital 
then spoke about the public health and safety impact of potential recreational marijuana legalization. He 
compared and contrasted it to our history with alcohol legalization, and offered suggestions for how to minimize 
potential negative public health and safety impacts of recreational marijuana legalization.
Our afternoon session featured two experts on opioid abuse. Dr. Kathleen Palm Reed of Clark University 
focused on issues of relapse — what predicts relapse and what safeguards can be put in place to try to prevent 
relapse. Dr. Hilary Smith Connery of McLean Hospital and Harvard Medical School talked about dispelling many 
of the myths circulating about opioid abuse; she focused particularly on the use of medications to treat opioid 
addiction, and its co-occurrence with other mental health problems.
The Massachusetts Family Impact Seminars are a project supported by the Mosakowski Institute of Public 
Enterprise at Clark University. A core mission of the Mosakowski Institute is to improve the effectiveness of 
government and other institutions in addressing social concerns through the successful mobilization of use-
inspired research. 
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The goal of this seminar series is to provide objective high-quality university-based research to state 
legislators and their staff, who are well-positioned to make decisions based upon that research. Over the past 
six years, we have received high marks for our objectivity and the quality of the work we present, and we hope 
to maintain this reputation in years to come.
The Family Impact Seminars are where research meets policy on family issues. We are part of a national 
network of universities that do Family Impact Seminars in their states, with one university per state designated 
as the Family Impact Seminar site for that state. Please consult the following webpage for more information 
regarding the FIS around the country: purdue.edu/hhs/hdfs/fii
Overall, these Family Impact Seminars have two goals. First, we try to promote greater use of objective, 
non-partisan university research in policy decisions, and we do this through the presentations themselves; 
through discussions among the experts, legislators, and other seminar attendees; and through this briefing 
report.
Second, we try to encourage policymakers to examine the family impact of policies and programs. One way 
we do this is by encouraging policymakers to ask three questions:
(1) How are families, rather than individuals, affected by the issue?
(2) In what ways, if any, do families contribute to the issue?
(3) Would involving families in the solution result in better policies?
For more information about the Massachusetts Family Impact Seminar, please go to the following webpage: 
http://wordpress.clarku.edu/dhines/familyimpactseminars/ and/or contact me at dhines@clarku.edu. 
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The Family Impact Guide for Policymakers
VieWing pOlicies thrOugh the family impact lens
•   Most policymakers would not think of passing 
a bill without asking, “what’s the economic 
impact?”
•   this guide encourages policymakers to 
ask, “what is the impact of this policy on 
families?” “would involving families result in 
more effective and efficient policies?”
When economic questions arise, economists 
are routinely consulted for economic data 
and forecasts. When family questions arise, 
policymakers can turn to family scientists for 
data and forecasts to make evidence-informed 
decisions. The Family Impact Seminars developed 
this guide to highlight the importance of family 
impact and to bring the family impact lens to  
policy decisions.
wHY faMilY iMpaCt is iMpoRtant  
to poliCYMaKeRs 
Families are the most humane and economical 
way known for raising the next generation. 
Families financially support their members 
and care for those who cannot always care for 
themselves — the elderly, frail, ill, and disabled.  
Yet families can be harmed by stressful conditions  
—the inability to find a job, afford health insurance, 
secure quality child care, and send their kids 
to good schools. Innovative policymakers use 
research evidence to invest in family policies and 
programs that work, and to cut those that don’t. 
Keeping the family foundation strong today pays 
off tomorrow. Families are a cornerstone for 
raising responsible children who become caring, 
committed contributors in a strong democracy,  
and competent workers in a sound economy [1].
In polls, state legislative leaders endorsed families 
as a sure-fire vote winner [2]. Except for two 
weeks, family-oriented words appeared every week 
Congress was in session for over a decade; these 
mentions of family cut across gender and political 
party [3]. The symbol of family appeals to common 
values that hold the potential to rise above politics 
and to provide common ground. However, family 
considerations are not systematically addressed in 
the normal routines of policymaking.
How tHe faMilY iMpaCt lens Has 
benefiteD poliCY DeCisions 
•   In one Midwestern state, using the family impact 
lens revealed differences in program eligibility 
depending upon marital status. For example, 
seniors were less apt to be eligible for the state’s 
prescription drug program if they were married 
than if they were unmarried but living together.
•   In a rigorous cost-benefit analysis of 571 criminal 
justice programs, those most cost-beneficial 
in reducing future crime were targeted at 
juveniles. Of these, the five most cost-beneficial 
rehabilitation programs and the single most 
cost-beneficial prevention program were family-
focused approaches [4].
•   For youth substance use prevention, programs 
that changed family dynamics were found  
to be, on average, more than nine times more 
effective than programs that focused only  
on youth [5].
Questions poliCYMaKeRs Can asK 
to bRing tHe faMilY iMpaCt lens to 
poliCY DeCisions:
•   How are families affected by the issue?
•   In what ways, if any, do families contribute to the 
issue?
•   Would involving families result in more effective 
policies and programs?
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How poliCYMaKeRs Can eXaMine 
faMilY iMpaCts of poliCY DeCisions
Nearly all policy decisions have some effect 
on family life. Some decisions affect families 
directly (e.g., child support or long-term care), 
and some indirectly (e.g., corrections or jobs). 
The family impact discussion starters below can 
help policymakers figure out what those impacts 
are and how family considerations can be taken 
into account, particularly as policies are being 
developed.
family impact discussion starters
How will the policy, program, or practice:
•   support rather than substitute for family 
members’ responsibilities to one another?
•   reinforce family members’ commitments to each 
other and to the stability of the family unit?
•   recognize the power and persistence of family 
ties, and promote healthy couple, marital, and 
parental relationships?
•   acknowledge and respect the diversity of family 
life (e.g., different cultural, ethnic, racial, and 
religious backgrounds; various geographic 
locations and socio-economic statuses; families 
with members who have special needs; and 
families at different stages of the life cycle)?
•   engage and work in partnership with families?
ask for a full family impact analysis
Some issues warrant a full family impact analysis to 
more deeply examine the intended and unintended 
consequences of policies on family well-being. 
To conduct an analysis, use the expertise of both 
family scientists, who understand families, and 
policy analysts, who understand the specifics of  
the issue.
•   Family scientists in your state can be found at 
familyimpactseminars.org
•   Policy analysts can be found on your staff, in the 
legislature’s nonpartisan service agencies, at 
university policy schools, etc.
apply the Results
Viewing issues through the family impact lens 
rarely results in overwhelming support for or 
opposition to a policy or program. Instead, it can 
identify how specific family types and particular 
family functions are affected. These results raise 
considerations that policymakers can use to make 
decisions that strengthen the many contributions 
families make for the benefit of their members  
and the good of society.
aDDitional ResouRCes
Several family impact tools and procedures  
are available on the website of the Family Impact 
Institute (familyimpactseminars.org).
1    Bogenschneider, K., & Corbett, T. J. (2010). 
Family policy: Becoming a field of inquiry and 
subfield of social policy [Family policy decade 
review]. Journal of Marriage and Family, 72,  
783-803.
2    State Legislative Leaders Foundation. (1995). 
State legislative leaders: Keys to effective legislation 
for children and families. Centerville, MA: Author.
3    Strach, P. (2007). All in the family: The private 
roots of American public policy. Stanford, CA: 
Stanford University Press.
4    Aos, S., Miller, M., & Drake, E. (2006). Evidenced-
based public policy options to reduce future prison 
construction, criminal justice costs, and crime rates. 
Olympia: WA State Inst. for Public Policy.
5    Kumpfer, K. L. (1993, September). Strengthening 
America’s families: Promising parenting strategies 
for delinquency prevention—User’s guide 
(U.S. Department of Justice Publication No. 
NCJ140781). Washington, DC: Office of Juvenile 
Justice and Delinquency Prevention.
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 Taking a Hit: Assessing the Impact of  
Early Onset Marijuana Use on the Brain
 
by staci a. gruber, ph.D.   
pOlicy Brief 
marijuana is seemingly everywhere, from newspaper and television headlines, 
to online blogs and social media feeds, and it remains the most widely used 
illicit substance in the world. 
ReCReational MaRiJuana use in aDolesCenCe 
With the ongoing debates regarding legalization of recreational marijuana and approval of medical 
marijuana in more than 23 states, it is important to consider what children and adolescents are thinking. 
According to the most recent national Monitoring the Future Survey,1 16.5% of 8th graders, 14.8% of 10th 
graders, and 21.3% of 12th graders had used marijuana in the past month. Also, for the first time in the 
survey’s 40-year history, daily marijuana use (6%) was reported to be higher than daily cigarette use (5.5%) 
in this age group. 
Unfortunately, adolescence is a particularly vulnerable period for exposure to substances, including 
marijuana, because the brain not only continues to develop during this time, but critical reorganization of 
neural networks occurs. Through a process known as pruning, frequently used neuronal pathways are refined 
and strengthened, while weak connections are culled. During this period, the brain is primed for rewarding 
behaviors, and is marked by risk taking and impulsivity. 
The brain may also be more vulnerable during childhood and adolescence because it is “wired” 
for marijuana. The human brain is comprised of cannabinoid receptors designed to interact with the 
body’s natural chemicals; however, the main psychoactive component in marijuana, Δ-9 THC (delta-9-
tetrahydrocannabinol), also fits into these receptors. During adolescence, the level of cannabinoid receptors 
peaks, and accordingly, exposure to THC may alter brain function and structure in regions rich with these 
receptors. 
wHY MaRiJuana is not as HaRMless as YoutH belieVe 
Given this information, it is not surprising that marijuana use during adolescence has been 
specifically linked to deficits in cognitive performance as well as alterations in brain structure and function. 
Comprehensive reviews of marijuana smokers have revealed that teenage onset of marijuana use is 
associated with greater alterations than those who begin using during adulthood.2 Weekly or more frequent 
marijuana use during adolescence has been linked to reduced performance on measures of IQ, attention, 
memory, and processing speed; most notably, it has been linked to reduced executive functioning, which  
are processes involved in inhibiting impulsivity, shifting strategies, self-monitoring, and planning.2, 3 
Further, longitudinal studies have found that increased marijuana use predicts reduced attention4 and 
some aspects of memory.5 Neuroimaging studies have revealed that changes in brain function and structure 
underlie these cognitive decrements. Adolescent marijuana users demonstrate alterations in brain function 
across numerous regions.6 
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In addition, marijuana use during this critical period is associated with decreased integrity of white 
matter, which is responsible for efficient communication between and within brain regions. White matter 
changes may also be related to increased impulsivity. In one study, lower white matter integrity was related to 
higher levels of impulsivity specifically within marijuana smokers who began using regularly prior to age 16.7 
Taken together, regular exposure to marijuana during adolescence may disrupt healthy 
neurodevelopment. Given the high rates of marijuana use among adolescents and teens, this may suggest 
that a large proportion of youth experience some cognitive difficulties related to marijuana use, which are also 
likely to impact academic performance.
Despite this mounting evidence, perceived risk and harm related to marijuana use is at its lowest levels 
since the 1970s. These perceptions are likely due to ongoing debates regarding legalization of marijuana that 
often underscore the benefits of marijuana, while overshadowing potential negative consequences. 
In fact, the majority of high school seniors do not believe that regular marijuana use is harmful; less than 
32% believe that regular use is associated with great risk, which is a sharp decline from five years ago when 
more than 50% reported great risk associated with regular marijuana use.1 
In addition, the potency of marijuana (percentage of THC) is rising. Potency is estimated to have 
increased from 3.4% in the 1990s to 8.8% in 2008.8 Unfortunately, national trends also reveal an increase 
in the use of butane hash oil (BHO) and other concentrates, particularly among younger populations, which 
can contain up to 50-80% THC. This raises concern about whether marijuana users may experience more 
pronounced cognitive deficits and alterations in brain structure and function because they are using products 
with such high levels of THC. This is particularly troublesome because adolescence is a critical time of 
neuromaturation, with increasing evidence that the adolescent brain is more vulnerable to the effects of drugs 
than the adult brain. accordingly, those at the greatest risk for adverse consequences represent a growing 
population of consumers of marijuana, posing a serious public health concern.
tHougHts foR tHe futuRe: it’s woRtH tHe wait 
 At this point, policy has outpaced science, with critical questions regarding the effects of marijuana still 
unanswered. As policy is drafted, it will be important to consider how recreational and medical marijuana 
use differ. For example, many who seek out marijuana for medical reasons are drawn to products high in 
cannabidiol (CBD), which has therapeutic potential for a number of conditions and can prevent and/or 
mitigate adverse affects often associated with recreational marijuana use.9 
 In fact, the director of the National Institute on Drug Abuse (NIDA), Dr. Nora Volkow, commented, 
“CBD appears to be a safe drug with no addictive effects, and the preliminary data suggest that it may have 
therapeutic value for a number of medical conditions.” Research dedicated to understanding the differences 
between marijuana use (recreational vs. medical, adolescent vs. adult onset, THC vs. CBD content, etc.) 
is particularly important as more states continue to move toward legalization of recreational and medical 
marijuana. 
 Many policymakers, consumers, physicians, and the general public remain misinformed about marijuana, 
yet it has never been more important to understand the impact of marijuana on the brain, particularly 
in our nation’s most vulnerable population — adolescents and emerging adults. Efforts targeted at early 
identification, education, and intervention regarding the potential negative consequences of recreational 
marijuana use are critical as the nation grapples with understanding marijuana as both a recreational 
substance and a medicine. 
 While the message “just say no” was not particularly successful, “just not yet” is likely a more easily 
adopted message, especially if paired with meaningful data that resonate personally with adolescents.  
Empirically sound interventions aimed at identifying, delaying, and decreasing marijuana use among youth  
must be consistently implemented to optimize neurodevelopmental trajectories and minimize the impact of 
marijuana use on the developing brain. 
2016 massachusetts family impact seminar
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 as states consider legislation for both recreational and medical marijuana use, it is imperative to 
determine safe guidelines regarding the impact of marijuana on the brain, particularly during critical periods  
of neurodevelopment.
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Today, it’s an honor to come and talk to you a little bit about 
the ability to assess the impact of early onset marijuana use 
on the brain. What do we mean by that? What do we mean 
by early onset? What do we mean by impact on the brain? 
I’m going to get to all of that. 
First and foremost, I have no conflicts of interest to disclose 
and the research that I’ll present that is from my lab is funded 
by NIDA, the National Institute of Drug Abuse.
It’s always nice to follow a policymaker who literally says 
things like, “We know people are going to use marijuana, now 
what do we do about it?” In fact, that seems to be true. And 
you basically have to be living on Mars at this point not to 
realize that marijuana is everywhere. It’s in our newsfeeds. 
It’s in our social media. Every day there’s something new 
on the radio or the TV about potential negative impact of 
recreational marijuana, potentially unbelievable therapeutic 
potential of medical marijuana for yet another indication. It 
may cure everything. 
So it really is everywhere, and I have to tell you when I looked 
for images to put this first slide together. I didn’t have any 
paucity of data for people smoking marijuana pretty much out 
in the open. It just goes to show, it’s not hard to find.
Why is that? As I think you’re going to hear from our next 
speaker, marijuana is on everybody’s mind because of course, 
when we consider the stakes of marijuana. We now have 23 
states, plus DC and Guam, which have passed full medical 
marijuana laws. Another 18 have partial medical marijuana 
laws. Those marijuana laws are specific to one constituent of 
marijuana, which I’ll talk about in a few minutes.
Of course, recreational marijuana is legal in four states, plus 
DC. Then there are nine states that have not prohibited 
marijuana. That’s for now. A number of those nine states have 
pending legislation, as we do here in Massachusetts, with 
regard to the issue of legalizing recreational marijuana use. 
This is why everybody is talking about it. It’s on everyone’s 
mind because it’s across the country. You cannot escape it. I 
was talking to one of my colleagues earlier, and I realized that 
I’ve been at my hospital almost 27 years, and of those 27, I’ve 
been involved in marijuana research for 25. So even though 
we’re now talking about the green rush, trust me, it’s been 
going on a lot longer than the last few years.
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So that’s what people know about marijuana. We’re talking 
about it. It may be good. It may be bad. Some of the things 
that people aren’t necessarily aware of are some of the better 
points that come from these wonderful national surveys. 
Monitoring the Future is a wonderful survey that basically 
assesses our 8th, 10th, and 12th graders across the country, 
not just with regard to marijuana use and alcohol use, but for 
all sorts of things. We get this great data every year, and every 
year we look at different use rates of prescription drugs, non-
prescription drugs, marijuana, alcohol, you name it. Then of 
course, we have data from SAMHSA and other organizations 
telling us about use rates in general in the population. 
What we know, currently, is that marijuana is the most 
widely used illicit substance worldwide, not just in the US. I 
say illicit because currently, let’s just remember, it is a class 1 
substance. So according to the DEA, it’s a class 1 substance, 
just like heroin and LSD. It may be a little bit counter to what 
people think of when we think of legalized medical marijuana 
use in states, because in fact, it is still a federal offense to  
use marijuana. 
However, over 5 million Americans report daily marijuana 
use, and almost 19 million report use within the last month. 
These are not small numbers of people. Of those folks who 
are using, more than 8 million report using heavily. What do I 
mean by that? Heavily is defined by more than 20 days of use 
in a month, in this particular case.
Among teens, very germane to us today, when we think 
about the impact of some of these things on families and our 
teens, our most vulnerable population. For the first time, the 
Monitoring the Future study has basically demonstrated that 
there are more high school seniors who smoke marijuana 
every day at 6%, than use cigarettes at 5.5%. First time. 
We also see about 1 in 8 high school seniors get behind the 
wheel after smoking marijuana. That’s compared to 1 in 11 
who get behind the wheel after drinking. I don’t even want 
to talk about the numbers who get behind the wheel after 
doing both because it has some very special and unfortunate 
circumstances when you couple them together.
 In the past month, marijuana use for the first time, in  
the Monitoring the Future Study, has demonstrated that use 
rates are starting to level off. I used to give talks like this and 
say use rates are continuing to climb. They’re now starting 
to level off, but among 10th graders for example, 14.8% 
are using. With 12th graders, over 21% are using, and that 
number, again, is holding steady. It didn’t increase. However, 
what’s not holding steady is the perception of risk and harm 
associated with marijuana use.
I’m going to draw your attention to this graph on this side. If 
you look at the far right of the graph here, you can see that 
between 2014 and 2015, the number of high school seniors 
that perceived great risk or harm associated with marijuana 
use dropped significantly from over 36% to just under 
32%. That was in one year. Perception of risk and harm is 
continuing to drop. 
That’s our first really important take home message. Why 
is it continuing to drop? Probably because of our ongoing 
discussions and debates about the potential utility of things 
like medical marijuana and the fact that four states plus DC 
now have recreational marijuana that’s legal with a number 
of other states, including Massachusetts, with pending 
legislation.
Is marijuana as harmless as our youth are led to believe?  
Long ago before the advent of MRI technologies which allow 
us to look at the brain over time in a non-invasive, non-
harmful way, we believed that the human brain was done 
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with regard to development by the time we hit puberty. Poof. 
Sexual maturity. We must be done. Nothing else is really 
happening. 
In fact, we now know that the brain continues to develop 
throughout the second, and into the third decade of life. So, 
the brain basically develops from the back to the front and 
from the bottom to the top. Areas involved in basic functions 
mature first, like senses and the ability to move: our limbic 
system. 
Parts of the brain that are responsible for things like top-down 
processing, what we call the seat of executive function. What 
do I mean by that? What are executive functions? The frontal 
part of your brain is the last part to become fully developed, 
and in fact, the part that’s responsible for things like planning, 
being able to inhibit inappropriate responses, being able to 
control impulses. Very last part to come on line. We actually 
have the term executive function because we think of the 
frontal cortex as the brain’s CEO. Think of it as being in 
charge, pretty much of everything. So just remember, it’s the 
last to become fully developed.
During development, especially adolescence, the brain is 
particularly vulnerable, not just to marijuana, but to things like 
drugs, illness, and injury. It is under construction. It’s not fully 
developed, so almost anything potentially could impact the 
system.
We have the term marijuana, and we hear it and use it pretty 
freely. In fact, it’s not just one thing. This is another really 
critical point for all of us to remember. Marijuana really is 
a term that’s used to describe anything that comes from 
the plant Cannabis Sativa L, of which there are hundreds of 
constituents. We know there are different strengths and 
species of marijuana. 
 My recreational users are very happy to tell me the 
differences between Sativa strains, which are energizing  
(“I feel so happy”), and Indica strains, which tend to mellow 
them out and relax them. Most people use a hybrid, but 
the important thing to remember is that the constituents of 
cannabis, the actual chemicals in the plant itself, are different. 
They are not all the same. 
The most common constituent that we talk about is Δ9 
tetrahydrocannabinol. THC is what gets you high. That’s the 
constituent that most recreational users are looking for in 
their marijuana. In fact, if they don’t get it, they really want 
their money back. I heard that last week. 
So recreational strains are particularly high in THC. I can tell 
you that over the last several years, THC levels are continuing 
to increase in marijuana. Our recreational users are averaging 
somewhere between 12% and 14% THC. I’ll show you how 
that is different from years past.
Cannabidiol is something we’ve often heard about or more 
recently heard about in the media. It’s another primary 
constituent of the same plant, except it’s not psychoactive. 
It’s been shown to have potentially therapeutic indications for 
a number of conditions. Not typically favored by recreational 
users. If you get something that’s not high in THC, you want 
your money back.
I draw your attention to the bottom right of this slide. THC 
is in purple. Notice how similar that structure is to what is 
to the right of it. That’s one of our brain’s own chemicals 
called Anandamide. As it turns out, we actually have our own 
cannabinoid system: the endocannabinoid system, consisting 
of chemicals and receptors. Basically the endocannabinoid 
system that we have is responsible for growth and 
connectivity of neurons. It’s responsible for keeping a pretty 
homeostatic environment. Mood, memory, pain, and appetite 
are all regulated by the endocannabinoid system.  
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So we have these receptors, but as you saw, it’s pretty similar 
in terms of Anandamide to THC. As it turns out, THC binds 
to these same receptors that we have, and those yellow 
dots throughout the brain basically demonstrate where we 
have these receptors, and there’s almost no brain area that’s 
excused from having these receptors.
When you use marijuana, especially if you’re smoking or 
vaporizing, which is the fastest way to get high, it binds to 
these receptors and you get an effect. So it affects a number 
of different parts of the brain. 
THC exposure, especially during adolescence or what we 
would call a period of vulnerability (remember I told you 
that brain is still under construction), may actually disrupt 
the way that neurons are supposed to be developing as a 
result. That’s my take home point here. As a result, there have 
been a number of studies that are particularly focused on 
the impact of early onset marijuana use. Is there, in fact, an 
impact of using marijuana early while the brain is still under 
construction?
There have been studies that look at age of onset of 
marijuana use, but no studies until more recently had really 
looked at those with early onset use. What do I mean by that? 
For my own data, we tend to put people in classifications 
of early onset users as those who begin a pattern of regular 
consistent use prior to age 16 versus those who begin using 
later. Would there be a difference if we looked at them head-
to-head? Not just does earlier onset make a difference,  
but also do people look different from those who started 
smoking later? 
I’ll show you some data from other folks’ studies, and data 
from my own just as a way of making it a little bit more real 
world. Remember that these studies are basically dependent 
upon recruiting people from all around this area, and sadly,  
I have no trouble recruiting. I’m just going to say that. For our 
recreational studies, we have no trouble getting folks who are 
interested in participating, which is a great thing. But certainly 
we have a number of people who are using. 
We recruit from the local community. We do a very 
comprehensive screen to make sure that folks meet eligibility. 
What do you have to do to get into one of my studies? For 
our chronic heavy smoking studies, people have to smoke a 
minimum of 1,500 times in their lives. They have to report 
smoking 4 or 5 of the last seven days. Their urine has to 
be positive for cannabinoids, and they can’t have any other 
psychological or medical condition. We also recruit healthy 
controls and they’re matched pretty well with one exception: 
They can’t have used any substance, even marijuana, more 
than five times.
They come into our lab, and we give them a lot of different 
assessments from clinical and diagnostic interviews, to 
clinical state measures, to see how they are with regard 
to mood. Substance abuse history is pretty extensive 
for themselves and their family members. We do a very 
comprehensive cognitive battery where we use pencil and 
paper measures and computerized tasks to look at the 
way their brain is functioning, and, of course, a suite of 
neuroimaging measures so that we can look at brain structure 
and function and in some cases chemistry and connectivity.
Our goal is to examine the impact of early onset use on the 
brain. Is there a difference in frequency and magnitude of 
use? What if you start using early, but you don’t use much? 
Or you don’t use too often? Does that matter? These are 
some of the questions that we like to ask.
2016 massachusetts family impact seminar
18
To summarize what we know in general from studies of 
cognitive performance, I can tell you that adolescent and teen 
onset of marijuana use is typically associated with greater 
deficits on a range of cognitive measures. Most specifically, 
the most commonly reported difficulties are in things like 
verbal memory, executive functions — these things mediated 
by the frontal cortex — and processing speed.
We also have some reports of reduction in IQ in one 
longitudinal study that’s been reported. We can talk about 
that during the question and answer period if anybody wants 
more information about that. Our own studies have basically 
demonstrated that early onset users, compared to late onset 
users, use twice as often and almost more than 2.5 times as 
much marijuana per week, as those who started smoking 
after age 16. So that’s pretty significant.
When I talk about these executive functions, what do I mean? 
There are a lot of different measures we give, but I love this 
one because it’s very colorful. This is called the Stroop color 
word test, and some of you may be familiar with this. Some 
of your kids may have this app on their phone. You may have 
seen this in graduate school. Very simple. Three conditions. 
The first: color naming. Subjects simply name colors. They are 
red, blue, and green. Single syllable colors. Nice and easy, as 
quickly as they can. Then we have words printed in black ink, 
and subjects are asked to read the words. Reading is the most 
automatic process you have. You can’t help but read a word 
printed in your native language. It’s very automatic. 
Then we have the interference condition. Now we have words 
printed in different colored ink than they’d spell, and what 
we’d like you to do is inhibit — use that frontal cortex and 
don’t read the word, but name the color of the ink. It sounds 
very easy, and probably the first few you would do really well, 
and then nobody wants to be singled out because invariably 
somebody makes a mistake. I get a lot of different responses 
that are not red, blue, and green, by the way. They’re also 
single syllable. 
So we do this task, and it’s very interesting because what 
we’re really looking for is how well they do the interference 
condition. We look at smokers, and split them into early onset 
and later onset users versus controls. The controls are in blue. 
The late onset group is the dark green bar, and the early onset 
group is the light green bar. 
When you look at smokers versus controls, they look 
different. But it turns out the differences between the two 
groups — smokers and non — are almost exclusively driven 
in every case by the early onset group. I draw your attention 
to the first panel on the above slide: percent accuracy. 
Significantly lower accuracy in the early onset group 
compared to the later onset group and the controls. 
Commission errors are a direct measure of a failure to inhibit 
an inappropriate response. The higher the commission errors, 
the worse they are doing at the task. Significantly higher 
commission errors in the early onset group compared to the 
others. This is critically important. It’s not just smokers as a 
whole. The early onset group is really driving it.
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I spend a lot of time doing brain imaging and we have a lot of 
different techniques that we utilize. Everybody in this room 
definitely is familiar with MRI, right? Magnetic Resonance 
Imaging. It’s really revolutionized the way that we are able to 
do neuroscientific experiments. It gives us a picture of what 
the brain looks like, and we can actually measure discrete 
areas of the brain. Gray matter, the hard working neurons part 
of the brain versus white matter, which connects brain regions 
to each other.
FMRI — pretty great technology — allows us to look at how 
the brain is working during tasks. Then diffusion imaging or  
DTI allows us to look at how organized or coherent white  
matter is. What’s the strength of the white matter connection? 
Again there are a lot of other techniques. I’m just going to 
highlight these really quickly. 
To summarize what we know in general about FMRI studies 
of individuals who use marijuana, specifically during 
adolescence: What we see are different patterns of brain 
activation in those who use early versus those who don’t. 
These are predominantly during tasks that require additional 
control, memory or working memory, reward processing, and 
executive functioning, the last part of the brain to become 
fully developed. 
 
This is data from my own lab. Here’s that same Stroop 
test. The interference condition. Now they’re doing it in the 
scanner. You don’t have to be a neuroscientist to know that 
these two images look different, and if anybody has any 
questions about how these data are analyzed or acquired, we 
can certainly talk about it at the break. 
You can see that the control subjects have a very discrete area 
of activation — this is within the cingulate cortex — versus 
the smokers, which have a much more diffuse pattern. What 
happens when we split the smokers into those with early 
and late onset? I want to tell you, the early and late smokers 
are matched for absolutely every variable in terms of age, 
education, SES, everything we can match them on, except 
the age at which they began using and the fact that they’re 
using more often and in higher amounts. Here we see that the 
early onset smokers have a very different pattern of activation 
from the late onset smokers. Late smokers are activating 
predominantly the same region as the controls, but not the 
early onset group.
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When we think about brain structure, we know across 
studies, adolescent marijuana smokers have exhibited 
changes in shape, mass, and volume in a variety of brain 
structures. We’ve also seen changes in thickness of the 
cortex overall. Depending on which areas you’re talking 
about, sometimes we see adolescent marijuana smokers 
with thinner areas, sometimes the areas are thicker. It really 
depends on the region. 
We’ve also seen changes in density and gyrification. What 
does that mean? We’ve all seen those pictures of the 
brain and people say, “What are those little folds?” That’s 
gyrification, a measure of the folds within the brain’s gray 
matter. What do all those things mean? Basically they boil 
down to the fact that those types of changes represent 
changes along the underdevelopment trajectory, differences 
in their development over time. And they appear to be related 
in each case to cognitive difficulties, relative to those who 
start smoking later. 
Changes in gray matter have been reported to be associated 
with increased executive dysfunction and poor memory. 
Decreased thickness areas are related to a poor ability to 
accurately perceive their own subjective negative emotional 
state, so they’re less in touch with how they’re feeling. 
Decreased gyrification, or fewer folds, has been associated 
with worse performance on complex attention tasks.
Diffusion sensor imaging is a way that we can measure the 
coherence and organization of white matter, and again, I think 
of white matter as the brain’s subway system, connecting 
one region to another for fast and efficient communication. 
You can have all of the hardworking neurons from your gray 
matter that you can possibly have, but if there is no way 
that you can communicate that to another brain region, it 
doesn’t matter. So DTI allows us to measure organization and 
coherence. DTI gives us a number of measures, one of which 
is called FA or Fractional Anisotrophy. That’s just the measure 
of how well organized the white matter fibers are.
This is an image that demonstrates the differences between 
smokers and controls, just in general. What you see in green 
is just a white matter skeleton, and what you see in yellow are 
the regions that are different between smokers and controls. I 
draw your attention to the top part. See the big smile? That’s 
the very front curve of the largest white matter structure of 
your brain, the corpus callosum, which separates the left and 
right hemisphere of the brain. That region, on the left and 
right side, also projects significantly to the frontal cortex. 
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So, what do we see when we look at smokers versus controls, 
and smokers divided into early and late onset? Once again, 
early onset smokers have significantly lower white matter 
organization relative to the healthy controls. Not quite 
significant when we compare them to the late onset smokers. 
That’s true in both the left and the right side. 
Actually, when we took a closer look, it turns out that earlier 
age of onset was related to lower white matter integrity 
across the board. This is true not only in the one region I 
pointed out, but in a number of regions. 
Let me say this again, the earlier you start smoking, the lower 
the white matter organization. This is a really important point 
because it argues for a structural brain change secondary to 
early exposure to marijuana.
I mentioned that we give all of our folks a huge amount of 
assessments, and some of them are examiner-driven and 
some of them are self-report. The Barratt Impulsiveness 
Scale is a self-report measure of how impulsive people think 
they are, and there are three sub-scores: attention, motor, 
and planning, and then there’s a total. “I do things without 
thinking,” or, “I act on impulse”: subjects rate themselves. 
The smokers are in green. Controls are in blue. Across the 
board, smokers are more impulsive by self-report than the 
controls. I wondered, given what we know about this and the 
fact that we just saw early onset was associated with lower 
white matter, is there a relationship between impulsivity and 
white matter? 
In fact, it turns out that there is. The black line represents 
smokers as a whole, and on the vertical access, what you see 
is the impulsivity total score and the horizontal access is that 
white matter measure. No relationship in smokers as a whole, 
but when we split them into late onset smokers, that’s the 
green line and still no relationship — but look at the light green 
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line. That’s the early onset group. What we see is a significant 
relationship between lower white matter organization and 
higher impulsivity. 
Remember the take home message: Earlier onset of use, 
lower white matter organization. Now what we see is 
lower white matter organization is associated with higher 
impulsivity only in the early onset group. This is incredibly 
important and present in both the left and the right side of 
this brain region. This is something to keep in mind. In fact, 
the idea that it’s only related to the early onset smokers really 
bears much greater investigation. 
To summarize these points, we know that studies of 
recreational use have reported cognitive impairments, 
particularly in those that begin using in adolescence. We see 
changes in a number of domains including processing speed, 
attention, memory, and of course, executive function. Early 
use is also associated with alterations in brain structure and 
brain function, relative to both late onset smokers and the 
controls.
The alterations or changes are more pronounced in those 
who begin using earlier, and in the early onset smokers 
specifically, there’s a relationship between lower white 
matter organization and higher impulsivity. This is like the 
perfect storm for families. So we have early onset exposure 
to marijuana, reduced white matter, maybe increased 
impulsivity.
We know that over time, a number of campaigns like “Just 
Say No” didn’t really work. In fact, I have people who come in 
and say, “If somebody tells me just say no, I’m saying yes, just 
go away.” I get it. We find at least for a number of our folks, 
“Just Say Not Yet” is a more easily adopted message. You 
explain to folks that we’re not saying never, we’re saying not 
now. We’re saying your brain is under construction and that 
it’s vulnerable. It’s incredibly important. 
Our kids, our adolescents, our emerging adults are smart. 
You have to make them your allies in this and explain to them 
that there’s data that suggests that if you expose yourself to 
high levels of the substance, the chances of having a negative 
impact are greater than if you didn’t. 
This is especially important given the rising potency that 
I alluded to earlier. We know that the average potency of 
what we call bud that people were smoking in the 90s, was 
just under 4%. The national average based on seizure data, 
seizure from law enforcement, was just under 10% in 2013. 
I want to make the point about more popular very novel 
methods. People are incredibly creative about how they’re 
using marijuana. Concentrates, for example — shatter, budder, 
wax. Budder contains over 50% THC. In some cases, over 
80%. Shatter, 80%. 
Of course, these trends raise concern that these adverse 
consequences that we see with marijuana may be even 
worse, especially in our youngest consumers. There have 
been no controlled studies on the effects of concentrates 
on the brain. Not one. What we know is from recreational 
marijuana studies of primarily smoked or vaporized products, 
not concentrates.
2016 massachusetts family impact seminar
23
I won’t get into this too much because I think my esteemed 
colleague will get into this, but in terms of thinking about the 
future, it’s important to remember things like edibles. They 
are incredibly appealing to kids. Who doesn’t want a gummy 
bear that looks like that or a brownie that looks so delicious? 
We have issues with accidental ingestion, and of course, 
many of these products are targeted for kids and adolescents. 
It’s really important to remember as we encounter this next 
ballot initiative about legalizing recreational use. One package 
may not be one dose. Colorado spent $10 million going 
through a whole packaging thing and making sure one unit 
dose was 10 mg of THC only. 
Remember that your body or brain does not process edibles 
in the same way that it processes smoked or vaporized 
products. There is a much, much longer rise time, the time 
until you feel the effect, and it lasts a lot longer. These are 
important things to keep in mind.
When we consider recreational marijuana, it’s important 
to remember that what we know so far is based on 
studies primarily focused on THC. That’s one constituent 
of marijuana. Just one. It’s important to remember that 
medical marijuana products very often have other things 
like cannabidiol that are present which are shown to have 
potential therapeutic indications.
There’s also the potential for risk. I can’t tell you how many 
kids say to me, “How can something be negative if in fact 
they’re using it as medicine? My mom’s best friend uses it as 
medicine; why can’t I use it?” We run the risk of accidental 
exposure because kids are misperceiving the intention of use. 
We saw that although medical marijuana has been around for 
two decades, policies outpace science. We do not have any 
empirically sound studies of the impact of medical marijuana 
on the brain. We have two studies ongoing in my lab, but we 
are in the very early stages.
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Together these findings underscore the importance of early 
identification and treatment of those who are using marijuana 
early. We know that exposure during a period of development 
may result in long-term changes. What happens after folks 
stop using? We actually have a cohort that has stopped using 
marijuana, and they don’t look the same as current smokers, 
which is encouraging. 
Educational opportunities for the public are critical to inform 
families of the impact of early-onset use. Youth need to be 
informed of the risk. You have to explain what we really know. 
Those who see higher risk associated with marijuana are 
less likely to use, but you saw perception of risk and harm 
continues to drop. 
Families should encourage an honest, open dialogue, and they 
should engage in the dialogue. Part of the problem is a lot of 
folks don’t want to talk about it. I have a lot of families who 
say my kid doesn’t use it, and the kid looks at me. 
So as states consider legislation for both recreational and 
medical marijuana, it’s important to determine safe guidelines 
regarding the impact of marijuana on the brain, especially 
during critical periods of development. We need more 
research on the scope of use, and we have some data from 
other states out west like Colorado that have suggested 
that there may not be the biggest change post legalization, 
but some of the data actually says there is change, post 
legalization, in terms of the rates and modes of use. 
We have to better understand the impact of marijuana on 
driving; the academic and social impact, and of course, close 
the gap between science and policy.
Adolescence is a time for neural maturation. Those that are at 
the greatest risk for adverse events or adverse consequences 
represent a growing number of the consumers of marijuana. 
Thank you for your time and attention.
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Question anD answeR
audience:  I have a question on age 16…[inaudible] early 
onset as the brain continues to develop until 30.
stacy gruber:  We actually chose 16 for a number of reasons. 
There is some evidence to suggest that we were far enough 
past the second wave of these progressive and regressive 
events that happen in the brain during development. There 
were also some other studies that had used 16 or 17. And 
it’s all about finding something that lines up with what we 
already know. Sixteen is also a time that kids are pretty 
firmly ensconced in high school, and this is when the threat 
of potential exposure really becomes greatest, although I’ve 
got folks in my study who are 12 and 13. So that was why we 
chose it. If only there was something that told us exactly  
what the right time was, that would be terrific.
audience:  But you picked a [inaudible] so I can smoke  
as much as you want.
stacy gruber:  I think it’s important to get out that we’re 
not saying that we don’t see changes in those folks. We’re 
just seeing a specific sort of incrementally worse set of 
performance from folks who are using regularly prior to age 
16. It seems to be worse the earlier folks are using. It’s not to 
say you get a free pass at 17. In fact, car rental companies: 
What do they know that other folks don’t know? They don’t 
rent to people before age 25. Right? Okay. But you can vote 
and buy liquor, 18-21. It seems strange to me. I think those car 
rental companies have some scientific board working behind 
the scenes.
audience:  Do you think there’s a link between earlier uses of 
marijuana to specific more hard line [inaudible] as opposed 
to other countries that have a more liberal progressive drug 
policy that would mean a lower, earlier usage of marijuana? 
A lower use of alcohol. Level of abuse. That doesn’t have a 
puritanical very strict alcohol policy.
stacy gruber:  That’s a good question, and I think that it’s a 
two-part question. We’ve heard a lot of theories related to 
the gateway theories. So, does early use of marijuana lead 
to the use of harder drugs? Does marijuana itself prime the 
pump that is the reward circuitry in the brain for other drugs? 
I think that the data for that theory, separate and apart from 
the psychosocial aspect of whether we do or don’t allow it 
here, is different. I don’t think there’s a tremendous amount 
of hard evidence suggesting that marijuana is a gateway 
drug. It’s more often that folks who use hard drugs have 
used marijuana, but typically, when you query them, they’re 
around people who are using other drugs and the folks from 
whom they’re getting marijuana are often offering them other 
substances. It’s not that marijuana created the difference. To 
your other point, I think that’s a great question. You know in 
other places where we have much more liberal views, there 
are lower rates of abuse. Right? We don’t have abuse and 
dependence anymore. We have use disorders. We don’t say 
that. But in fact it’s a really important consideration. I’m not 
sure I know the answer to it. It’s a great thought, though, and 
I think we’ll maybe start to see some of that data come out 
from states that have a more liberal policy, but I don’t know.
audience:  Are there other risks that you know about or other 
risks in [inaudible] states that may pose similar or greater 
risks to adolescents?
stacy gruber:  Marijuana? Sure. I think that it’s hard to come 
up with an absolute relativity index. Like, what’s the number 
one greatest risk for the adolescent brain? I think certainly 
there have been a number of reports in terms of alcohol 
and other drugs that demonstrate similar detriments, and 
I’ve heard a lot of people say, “But it’s not as bad as people 
who are drinking very heavily from the time they are kids.” 
We don’t have a huge amount of longitudinal data. We’re 
about to start. Several governmental agencies have this great 
longitudinal study planned called the ABCD Project which 
will look at 10,000 kids age 9 and 10 to begin with, and follow 
them pretty much for a decade, to see what has the greatest 
negative impact. It’s a great question. I get it a fair amount. 
How much more harmful is this than something else? And 
the answer is I’m not sure we know. I think the point is it’s not 
harmless. I think that’s the thing to keep in mind. Are there 
things that are more harmful to the brain? Likely, yes. In fact, 
we see that. Does that mean that this is a benign substance? 
No. 
audience:  Interesting. I work with young men and 
[inaudible] a lot about minimizing their trauma impact and I 
understand that, and what I find so troubling about your data 
is not only are they using it to manage the trauma impact of 
their lives but to [inaudible] the need to [inaudible] transition 
and [inaudible] life. And having these [inaudible] it impacts 
the impulsivity to manage healthy relationships, to navigate 
conflict and that it manages something for the [inaudible] 
and the long-term outcomes for them are profound. How do 
you feel?
stacy gruber:  I agree with you, and it is somewhat stunning 
to us as well. I think for those folks –and you know there’s 
been a lot of talk about alternative therapies for folks with 
trauma histories, and in fact we see a lot of folks with a lot 
of trauma who are self-medicating with marijuana. We’ve 
all seen the PTSD data where people will swear to you that 
marijuana helps them, and it may in part be true. What’s 
more likely true is that if we were able to isolate and allow a 
cannabidiol specific — a cannabidiol heavy product with just 
a touch of THC — we may see a very different outcome, and 
that’s sort of poised for the future and it’s something that I 
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hope we are able to spend a fair amount of time and energy 
on because we need to. The number of people who have 
survived trauma is staggering, and the things that they turn 
to, including marijuana, deserve attention. 
audience:  So before this longitudinal data, how can you 
differentiate on looking at images and data what makes them 
more likely to use?
stacy gruber:  Excellent question. Cross sectional data is 
limited. That is, we don’t know about cause and effect. How 
do we know, for example, with regard to the white matter 
data — which I find stunning and incredibly disturbing — how 
do we know that those people weren’t more predisposed 
somehow to use earlier versus the white matter now — is it 
antecedent or a cause? Is it causative or an outcome? And 
the answer is we don’t really know. Interestingly, the earlier 
the onset of use, that relationship between earlier use and 
lower white matter, tends to suggest there is a relationship. 
That exposure is what’s causing this, but to really definitively 
know that for sure, you need longitudinal studies. We also 
need longitudinal studies to follow some of these folks out. 
They don’t all look like potatoes. You know these guys are 
doing really, really well, and they’re well matched to our 
controls for IQ, which is well over 116 and 118. These are  
guys who are doing pretty well. These are not folks who 
don’t have lives. They’re college students. They’re paralegals. 
They’re dental hygienists. You know them and see them  
every day. That’s the thing. They’re everywhere. That’s 
the great question in terms of what longer-term use or 
abstinence results in with regard to recovery of function  
and brain structure.
audience:  I work for [inaudible] and [inaudible] of 
[inaudible] but we see in so many of our cases involving 
violence and we get direct testimony from people who 
have participated in that violence [inaudible] or just were 
observers to that violence, marijuana is almost always 
present and the idea — it’s an eye opener for me that your 
research around impulsivity. I guess impulsivity can mean 
different things, but impulsivity to act violently. There is a lot  
of research going on that I would say that might be an area 
where [inaudible] everyone thinks of someone smoking 
marijuana they’re just like — 
stacy gruber:  Mellow.
audience:  They’re mellowing out.
stacy gruber: Not everybody.
audience:  Yeah. And obviously for some people they can 
have very violent reaction.
stacy gruber:  So the big question for those folks is what else  
is going on. What else is happening with regard to genetic 
predisposition or if we just take the marijuana — I hate 
to say this. I think some of the only folks who are getting 
samples of products from our medical marijuana users 
and our recreational users. What’s in their weed? How 
high is the THC level? And when we think about legalizing 
for recreational purposes, are we going to put restrictions 
on the maximum level of THC and will we mandate some 
cannabidiol is present if you’re buying before the age of X? 
Twenty-five? Twenty-eight in fantasyland. But it’s a great 
question, and it’s something that shouldn’t go unnoticed, 
and I think that again, we see marijuana factoring into the 
equation across the board. The question is: what is it about 
the marijuana versus the person? And again, different strains. 
There are thousands of strains and hybrids. The mode of 
use and the way that people are using whether it’s a blunt, 
a spliff. They’re vaping. The product. The frequency and the 
magnitude all those things are important in terms of the 
outcome. We need studies to more clearly define what  
it means.
audience:  Do you have any plans to change the conversation 
with children and adolescents about marijuana as like to 
make it more tangible to them as opposed to just like the 
don’t do drugs message that police — 
stacy gruber:  So really the just say no, it really doesn’t work 
very well. We try to explain that during a specific period of 
time, they’re particularly vulnerable. And we say, you know 
you’re not going to be a kid forever. You have a long time. Isn’t 
it true that for those of us who are adults, we’re adults for a 
long time seemingly? There’s no rush. And we try to explain 
that they may not be giving themselves the very best chance, 
and again, most of these guys for our recreational studies 
are doing pretty well. The question is how well would they be 
doing if they weren’t using? So I think it’s important to point 
out that this is a period of time that’s a specific vulnerable 
period of time, and they need to wait. Like so many other 
things, there’s plenty of time to do it, and if they’re going to 
do it, do it responsibly. Don’t hit it every single day, six times 
a day. Don’t have a product that’s 26% THC. There are things 
that you can advise, now that we have information. We didn’t 
have information for many, many years. 
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 Marijuana Legalization:  
Impact on Public Health and Public Safety
 
by John f. Kelly, ph.D. 
pOlicy Brief 
the social, legal, and political landscape surrounding marijuana legalization for 
recreational use has changed dramatically. “medical marijuana” initiatives have 
culminated in laws being passed in 23 states (and Washington D.c.) and allow 
a medical recommendation for the use of marijuana to help alleviate symptoms 
of a variety of medical conditions.  
 Colorado and Washington have now taken a further step of legalizing the cultivation, distribution, and 
commercial sale of smoked and edible marijuana for recreational use. This is the first time that a signatory to 
the 1961 international drug treaty, the Single Convention on Narcotic Drugs (the implementation of which in the 
United States was the Controlled Substances Act of 1970) has had at least some of its territories legalize the use 
of any currently illicit drug for recreational use. 
 Marijuana is a psychoactive drug that causes intoxication and psychological impairment, as well as 
addiction and other health consequences. As such, the broader availability, accessibility, and lower prices 
associated with legalization and commercialization are likely to increase exposure to and use of marijuana. 
 Because marijuana can cause harms to public health (e.g., addiction, cognitive impairments) and risks 
to public safety (e.g., drugged driving), we will likely see increased public health and public safety problems 
associated with legalization. 
 Marijuana contains psychoactive ingredients, such as delta-9 tetrahydracannabinol or “THC” and 
cannabidiol or “CBD”. THC, in particular, produces psychological and physical addiction, and is associated with 
changes to the structure and function of the brain. Increased exposure to the drug is associated with acute and 
long-term cognitive deficits (particularly among adolescents exposed to the drug), including psychiatric illnesses 
(e.g., psychosis) and long-term problems with memory and attention that persist even after cessation of a year 
or more.1 
 Intoxication with marijuana does not produce some of the severe psychological, emotional, and behavioral 
consequences often seen with legal drugs, such as alcohol. For this reason, it can be perceived as comparatively 
benign. Concentrations of the psychoactive ingredients (THC) have been increasing steadily in recent years, 
however, and the marijuana available today contains about 4-5 times the amount of THC that was used 
commonly during the 1960s. 
 Furthermore, even more concentrated forms have emerged in consumable products (e.g., “edibles”). Edibles 
can produce more profound intoxicating effects that have resulted in more emergency department visits than 
with smoked marijuana. This is caused in part by the delayed onset of the subjective experience of intoxication 
from edibles because absorption takes much longer through the stomach than through the lungs. Consequently, 
individuals perceiving no initial effects can continue to consume more and more, resulting ultimately, in 
uncomfortable and sometimes serious levels of intoxication. 
 From the public health standpoint, smoking marijuana is associated with addiction.2 Approximately 9% of 
 regular users of marijuana will become addicted. It is also associated with onset of serious mental illness,3, 4, 5  
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heart and lung complications,6, 7 injuries resulting from car crashes,8 IQ degradation and poorer academic 
achievement,1 poorer quality of life,9 and poorer educational and vocational performance.10 
 Increased exposure, and especially regular exposure during the critical developmental period of adolescence, 
is almost certain to increase the occurrence of these problems in exposed individuals and the population more 
generally. Importantly, like all drugs, the toxicity and harms are related to the dose and intensity of exposure as well 
as the length of the period of use. 
 From the standpoint of public safety, acute intoxication leads to psychological impairments (e.g., memory 
impairments, decreased attention, slower cognitive processing speed, impaired judgement, increased anxiety, and 
paranoia) that have obvious consequences for driving under its influence. Use of marijuana is associated with a 
two-fold increased risk of having a car accident while driving; the effects can last for up to three hours following 
consuming a dose sufficient to impair psychological functioning.11 
 Unlike alcohol, marijuana use and heavy use is not associated with violence. It is currently unclear whether use of 
marijuana is associated with increased risk of lung cancer, but smoking does increase risk of pulmonary harms. 
 While there is very likely to be increased exposure to marijuana in the population if it is made more available, 
accessible, and cheaper, proper regulation can reduce the degree of harm to public health and safety. The 
Netherlands has allowed commercial sales to occur in cafes, and it has enforced rules that limit the amount of 
marijuana anyone can buy in a single day, ban advertising completely, and prohibit sales to minors. 
 Allowing legal use, commercial cultivation, distribution, and sale, while simultaneously enforcing such 
restrictions, could help reduce expenditures from law enforcement and criminal prosecutions related to the 
drug’s illicit status while minimizing escalation of use.12 The financial savings from the eradication of costs to 
law enforcement and criminal justice expenditures due to its illicit status, must be weighed against increased 
law enforcement and legal costs that will accrue due to failure to comply with the new regulations of cultivation, 
distribution, and sale (e.g., illegal sale to those under age 21; driving while intoxicated, etc.). Alcohol prohibition 
was ended, in part, due to increased criminal activity in supplying alcohol illegally, but despite the end of alcohol 
prohibition, there are millions of arrests annually across the country related to alcohol (e.g., sales to minors,  
DUIs, violence/domestic violence) 
 Legalization goes much further than decriminalization. In Washington and Colorado, there are regulations in 
place to try to minimize harms to public health and safety. Many of these policies are borne out of the experience 
from alcohol and tobacco, with minimum purchase age being 21 years old and requiring licenses to sell the drug. 
Colorado does not allow advertising.13 Washington does, but has restrictions.14 
 There are other issues that will need to be addressed, such as second hand smoke exposure, quality control, 
and consumer protection. Potency (e.g., THC content “per serving”) will need to be standardized and labelled, and 
safeguards should be taken to ensure that the salable product is not contaminated by fungi, bacteria, or pesticides. 
There is also the question of how the products should be packaged and labelled and whether to list ingredients and 
potential health harms, including addiction risk. 
 Any legalization and commercialization of marijuana will need regulation, education, and taxation. Education 
initiatives will be needed to inform parents and young people about the potential harms and hazards associated 
with marijuana (especially during teenage years). 
 Taxes on the cultivators, sellers, and buyers of the product could be used to help offset its likely contributions 
to health and safety related harms. As with alcohol and tobacco, consumers are sensitive to price, and higher prices 
reduce consumption, particularly among those who spend a large amount of their available income on the drug 
(i.e., those most likely to have problems and encounter problems due to the drug). 
 Care must be taken, however, not to price the drug too high, as this can lead to black market sales with 
cheaper availability. To the extent that marijuana can cause population-level health harms and threats to public 
safety, price and availability are two central factors that influence such harms and threats. Lower prices and greater 
availability will increase use and related harms; higher prices and lower availability will have the opposite effect. 
 It is likely that if commercialization expands, greater financial resources and lobbying efforts by commercial 
growers could begin to change the policy and regulatory landscape over time, such that gradual erosion of 
enforcement efforts and any imposed restrictions on advertising, amount of daily purchase, warning labels, etc., 
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could occur. To prevent this, a proportion of the tax revenue should be spent on an independent oversight body that 
can provide ongoing monitoring and evaluation of these policies and regulations, such that they are not eroded for 
corporate gain at the expense of public health and safety. 
 The journalist, Henry L. Mencken, once remarked that for every complex problem, there is a solution that is 
clear, simple, and wrong. Drug policy, ultimately, should be about minimizing or eradicating harms due to drugs. 
Given that intoxicants are threats to public health and safety to some degree and at least some proportion of the 
population appears to want to use intoxicants, complete eradication of all harms is unlikely. 
 Policies to minimize harms have been implemented in the form of prohibition, decriminalization, or 
legalization. Each policy position has side effects. Effective policies should be devoid of ideology and based on 
rational data-based solutions that minimize harms. On the one hand, prohibition works. It dramatically reduces 
exposure in the population and consequently, minimizes related harms. On the negative side, due to the demand, 
it increases illicit black market and criminal activities, and leaves consumers, distributors, and sellers on the wrong 
side of the law. This drives up costs in law enforcement, criminal justice, and incarceration. 
 At the other extreme, legalization and unrestrained free-market corporate commercialization with largely 
unrestricted advertising and sales likely would lead to targeting of young people and other vulnerable sub-groups, 
and casualties would increase (as has been the case with alcohol). Decriminalization, as has occurred in Portugal, 
minimizes illegal consequences, but does not eradicate the black market and associated criminal activity. Drug 
problems will not be completely eliminated as a result of any particular position. Rather, we are at  
a new juncture where we will be choosing which types of drug problems we will have.
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Good morning everybody. Delighted to be here. Thank you 
very much, Dr. Hines, for the opportunity and invitation to 
come along and talk to you all today and be a part of this 
fabulous seminar. Thank you for coming. Let’s get started.  
I like this quote a lot. “For every complex problem, there is a 
solution that is clear, simple and wrong.” This was by Henry 
L. Menken, and applies particularly well to drugs and drug 
policy. Whenever you hear someone say all you’ve got to do is 
dot-dot-dot, you know immediately that that person doesn’t 
know largely what the nuances of the complex issues are at 
stake in drug policy.
So hopefully you won’t be leaving here today saying all 
you have to do is dot-dot-dot. That’s one of the goals that 
I want to try to get across. I want to inform you all about 
some of the things that we have learned and I have learned 
regarding the complexity of drug policy. I think ultimately, 
we cannot eliminate our drug problems. What we can do is 
try to minimize the drug problems by taking different policy 
positions, but ultimately we are going to have to choose 
which problems we are going to have.
What is marijuana? It’s a psychoactive drug. It produces 
addiction, as I’ll talk about. It produces, of course, euphoria. 
People like the feeling when they’re exposed to marijuana. 
It produces pleasant effects that people like to repeat. It 
produces intoxication. It has neurotoxic effects, and I’m 
going to distinguish between these three different pathways 
through which substances cause harm as I go through  
today’s talk.
It is the world’s second most favorite intoxicant/psychoactive 
drug after alcohol. Alcohol is by far the world’s favorite drug. 
transcript Of Dr. Kelly’s talK
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But cannabis is number two, and it is number two here in the 
United States.
When we think about addressing the “drug problem,” there 
are different broad policy positions we can take, and this is a 
nice graphic that highlights these different policy positions. 
You can see along the bottom of the graph, along the x-axis 
of this graph, on the left-hand side, is what we currently have 
federally: prohibition. In fact, all nations have signed onto a 
single narcotics convention. It was signed in 1960 prohibiting 
the use of illicit drugs other than alcohol and tobacco. So we 
have prohibition. 
You can see prohibition and de facto decriminalization, 
decriminalization, market regulation, leading on to legalization 
with a few restrictions, and then legalization with some 
restrictions, and legalization with few restrictions. Those are 
the different policy positions that can be taken regarding 
drugs. Up the y-axis going north there, you can see these are 
the number of health and social problems related to each 
policy.
You can see the two extremes on either end here: we’ve 
got prohibition on the left with a high degree of health and 
social problems, but we also see a high degree of health and 
social problems on the right-hand side. The two extremes 
are prohibition with full enforcement of prohibition and on 
the right-hand side we see full blown commercialization, 
unrestricted commercialization also producing health and 
social problems.
So how do we get to this point in terms of legalization? 
The states in light green are the states that have medical 
marijuana laws passed. The four dark green states and the 
District of Columbia are the states that have now legalized 
recreational use of marijuana. We have quite a few states 
already with medical marijuana. 
When we look at medical marijuana, it seems to be a magic 
potion that can cure many things, according to those who 
would advocate for its widespread use medically. In fact, this 
particular website said there was up to 259 conditions that 
medical marijuana could help with. I was immediately 
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skeptical because we only have 109 known medical 
conditions. So I’m joking. I don’t know how many known 
medical conditions we have, but anyway, it would be fantastic 
if it were true that it could have such a broad impact on so 
many conditions.
When we look at the data, we do know that marijuana does 
have, like many things that we find in nature, medicinal 
properties. We have FDA approved medications that have 
THC and cannabidiol as their constituents, and these have 
been used and passed FDA approval to treat things like 
nausea, increase appetite for cancer patients, and decrease 
spasticity among patients with multiple sclerosis. There is no 
doubt that it has therapeutic properties. 
 
What’s interesting is when we look at the scientific basis for 
medical marijuana, however. Remember medical marijuana 
is smoked marijuana. This is what we see. The left hand 
bar under each one of these major conditions for which it’s 
been studied, are studies on smoked marijuana. As you can 
see there are very, very few studies we have on smoked 
marijuana. This is the scientific basis for the recommendation 
for medical marijuana, and when we look at the studies at 
risk of bias, which have actually been done with medical 
marijuana, more than half of the studies are at risk of biasing, 
by un-blinding. 
In other words, when you actually do a study with smoked 
marijuana, people can often tell if they’re smoking marijuana 
or not. So it’s hard to find a placebo to really isolate the 
independent effect of the psychoactive drug. But it’s 
interesting, isn’t it, that medical marijuana has been passed 
by popular vote in so many states when there is so little 
scientific basis for medical marijuana? In fact, I can’t find any 
scientific basis for a physician recommendation. In an era of 
science-based medicine, evidence-based medicine, I don’t 
know what the scientific basis is for recommending that 
someone smoke marijuana. There is none as far as I can see. 
It doesn’t mean that it hasn’t got therapeutic potential, 
because clearly the constituents of marijuana do, but when 
we prescribe a drug or in this case recommend a drug is 
consumed, we should also know about things like side effects 
and interactions with other medications. Should you take it 
while you’re pregnant? Etc. These are the kind of safeguards 
that we usually advocate for when we’re recommending and 
prescribing a drug.
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When we look at cannabis, marijuana, I’ll ask you a question. 
Why should it be illegal? And why should it be legal? Well, 
we have taken a position that it’s bad, right? That somehow 
marijuana is bad for us and it’s bad for society, and therefore, 
it should be illegal. We certainly know it causes neurotoxic 
effects in the central nervous system, particularly among 
young people. What other kinds of harm does it do? 
This is a study that was done in Great Britain. It was 
replicated in Europe where they had 40 different experts 
from across different disciplines rate the harm. Sixteen harms 
attributable to various substances on these 16 different 
dimensions across 20 different substances. These are the 20 
most widely used/misused substances.
You see cannabis is right about in the middle there, so it 
wasn’t high harm. It wasn’t particularly low—somewhere in 
the middle in terms of drug-related effects and harms to do 
with toxicity and intoxication, addiction, etc. Interestingly, 
what they found in both of these independent studies was 
that alcohol was the top rated substance in terms of causing 
harm, overall. So this is harm to the user and harm to others. 
Alcohol came out top in both of these independent studies.
What are the arguments for cannabis legalization? Well, the 
war on drugs has failed. We hear this a lot. We’re locking 
people up far too frequently. We have 5% of the world’s 
population, but 25% of the world’s prisoners. Interestingly, 
of the 2.5 million people locked up, about half or a million of 
those are there for drug-related offenses. And the issue of 
racial disparities, in that minorities are incarcerated at high 
rates, even at the same level of use and possession. 
And legalization would reduce arrests, of course. It would 
certainly reduce arrests for possession, but it might increase 
arrests for violation of regulatory laws. For example, we have 
legalized alcohol. How many arrests do you think occur a 
year for alcohol in the United States? Any guesses? This is 
just violation of the laws governing alcohol use: 3 million 
every year. Three million arrests, and that’s after we legalized 
it. So, we would decrease the 700,000 arrests for illegal 
possession, but we might also increase or replace those 
arrests with violations of regulations of legalizing it.
Another argument for legalization is they’re going to do it 
anyway. People are going to do it anyway, so let’s just legalize 
it. That’s another argument. And that it’s not as bad as 
alcohol. It’s not as bad as tobacco and may even be good for 
you, right? It’s medicinal. Also, taxing it will bring in revenues. 
We’ll all be richer, and we can spend that money on good 
things, other good things that will make us a better society. 
Since the 80s, we have seen a dramatic increase in 
incarceration rates, particularly among men and particularly 
among minority men. 
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We’ve had overcrowding in prisons. You can see these 
bunk beds stacked three high. This is actually in a California 
cafeteria, so we are locking a lot of people up. 
If we think about the arguments for legalization based on the 
failure of the war on drugs, I said to you about 500,000 are in 
prison due to drug related offenses, but it turns out only about 
40,000 of those are related to marijuana.
By the way, this would be an argument for decriminalization, 
not legalization, if we were going to prevent the war on 
drugs and locking people up. So, ending the war on drugs by 
legalizing marijuana won’t do it. As I mentioned, it will reduce 
the arrests for marijuana possession. We have 700,000 
arrests for marijuana possession, but we don’t know whether 
those 700,000 arrests for possession will be replaced, 
as it has been for alcohol, with arrest for violation of laws 
pertaining to underage use, drugged driving, etc.
The other aspect is in terms of legalization is how to legalize. 
So, as I showed you on that graph before, we could legalize, 
have a state monopoly with no advertising. Make it legal. 
People can get it if they want it, but there’s no advertising, and 
you can keep the price below a black market level, so people 
don’t go to the black market.
You can allow commercialization, as we have done with 
alcohol and tobacco. One of the problems with that is that 
full-blown commercialization advertising industries rely on 
heavy users for profit. Eighty percent of alcohol is drunk by 
20% of users, and 50% by 10% of users. So, to make a profit, 
the industry has to rely on addicted heavy users, and they 
target people of vulnerable subgroups and young people to 
maximize the heavy rates of use that give them the profit.
If we make it more available and accessible, cheaper, and 
remove social stigma and penalties, and have an industry 
aggressively advertise it, undoubtedly we’re going to see 
increases in use. 
There is a question of whether marijuana could have a 
subtractive effect, and what I mean by that is if people were 
using marijuana, would they use less alcohol? And because 
alcohol by itself produces a lot of social harms, health 
harms, maybe we would see a net benefit from people using 
marijuana instead of alcohol? We don’t know the answer  
to that. 
But everyone knows this that prohibition doesn’t work. I hear 
this even from my colleagues at work. We tried that right? We 
tried that with alcohol. Eighteenth amendment and look at the 
mess that that got us into.
So we need to legalize, regulate, tax, and educate, just like 
alcohol.
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Then we had the 21st Amendment. In 1933, it legalized 
alcohol because of all the problems caused by prohibition. 
And this is what has happened: Now we have alcohol that 
is a legal drug, and actually the rates of addiction for alcohol 
are 3.5 times that of those for all illicit drugs combined. This 
is the latest data from a nationally representative sample, 
using the latest, standardized criteria for making a diagnosis 
of addiction, and we have obviously much higher rates when 
you give people access to an addictive drug like alcohol; it 
does produce higher rates of addiction.
So did re-legalization in this case put an end to our alcohol 
problems? Alcohol, as I mentioned, is an addictive drug. Of 
the 23 million people who have a drug addiction in the United 
States, about 18 million of those are addicted to alcohol. 
Alcohol is a level 1 carcinogen. It causes cancer. Less than 
1.5 drinks a day increases breast cancer risk by 25% in 
women. Not many people know that. Not many primary care 
physicians know that. Forty million individuals drink at levels 
that are harmful and hazardous. We have 100,000 deaths per 
year due to alcohol. It’s the third leading preventable cause of 
death in this country.
We get some money from sales tax revenue—and this is one 
of the promises of marijuana, that we could get some money 
from selling it. We get about $15 billion; $9 billion federal 
level and $6 billion state level tax revenue, but the cost is 
$250 billion. That’s 17 times higher. Who’s paying the tab? 
As I mentioned, we have 3 million alcohol related arrests 
each year for alcohol. So, if prohibition didn’t work, it’s hard to 
make the case from these data that somehow legalization is 
the answer.
Here’s an interesting question. If alcohol is so addictive and 
the majority of addiction cases in this country are due to 
alcohol, why don’t we have on the containers, “May cause 
addiction”? Any ideas? It’s a level 1 carcinogen in the same 
category as asbestos. How come it doesn’t say, “May cause 
cancer”? Or, “Alcohol causes cancer”? Why don’t we have 
that on our alcohol containers? I know the alcohol industry 
would be in favor of that. Right? Putting those statements  
on them. 
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When we look at the ways that substances can cause harm, 
we know that drugs cause harm in three related, but distinct 
ways:
(1) Through toxicity, which Dr. Gruber talked about in terms 
of neurocognitive deficits, impairments produced by exposure 
to the substance and particularly at critical developmental 
stages. 
(2) Intoxication is another one independent of toxicity. In 
other words, you can smoke a couple of joints, get high, fall 
down the stairs, get into a car and drive, and crash. So there 
are harms to just acute intoxication, independent of toxicity. 
(3) Also independent is addiction, which is the one that we 
are most familiar with—people getting hooked on a drug. We 
know that marijuana does produce addiction in about 9-10% 
of cases that are exposed to it.
We also know that early exposure increases that risk 
exponentially. So we have marijuana dependence increase 
about 17% if they start in their teens, and if you’re a regular 
user, you go to 38% risk of meeting criteria for a use disorder.
When we look at rates of use nationally, we find that 
marijuana is the most popular drug in terms of use. 
In terms of use disorders also, because it’s the most widely 
used. Because it does cause addiction, we see a majority of 
addiction cases when we look at the population in terms of 
the type of drugs, other than alcohol, of course. 
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Also for coming in for treatment, after alcohol, marijuana 
is the most common substance for which people seek 
treatment in this country, among young people, adolescents 
up through age 18 or 19. About 90% of adolescents coming in 
for treatment are coming in for a marijuana use disorder. 
Have we seen an increase? This is again nationally 
representative data. When we look at marijuana use disorder 
specifically, we can see roughly a doubling in the incidence 
of marijuana use disorder between 2001 and 2013. It causes 
addiction. 
What about toxicity? That was one of the other pathways 
through which substances cause harm, and Dr. Gruber 
really focused on this very well in terms of looking at the 
neurotoxicity. As Dr. Gruber alluded to, we don’t seem to see 
these kinds of neurotoxic effects with older adults. Again, the 
toxicity is in the dose. It’s how much you use that determines 
what kind of an impact you will have.
This is a systematic quantitative review of the studies that 
have been done looking at neurocognitive deficits attributable 
to marijuana intoxication. When they didn’t isolate those who 
were abstinent for about a month, they found that there was 
a residual neurocognitive deficit, but after 25 days, in adults 
they did not find any neurocognitive deficit among regular 
heavy users. But we do see it in adolescents. This notion of 
early onset and underage use given that states have legalized 
it at the age of 21, the way that we have with alcohol.
These are some studies from our lab. Dr. Gilman and Dr. 
Shista, from the Center for Addiction Medicine at MGH, 
have done some nice studies showing how exposure affects 
memory work and memory attention. 
One of the interesting things about this study was what 
happened when people stopped—Dr. Shista was paying 
people to stop for 30 days. So she paid adolescents who 
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were regular users to stop smoking, and then she measured 
their neurocognitive function and mood, and what she found 
was in that 30-day period, their mood actually improved. 
You can see their depression symptoms actually went down 
substantially over that 30-day period. People will tell you, 
marijuana made them feel better. Objectively, it actually 
tends to improve mood when people abstain, at least in that 
sample.
There are certain critical periods. Dr. Gruber very nicely 
mentioned this and explained this critical period of 
development seems to have unique long-term effects on 
development. This is a long-term study. It’s the best study 
that we have long-term that’s followed up 1,300 people from 
age 13, before they were exposed to any alcohol or other 
drugs, including marijuana. They followed them up for  
25 years, up to age 38. 
What they found is that only those who had smoked during 
adolescence had long-term deficits. They were heavy 
smokers during adolescence and had an 8-point lower IQ on 
average over this 25-year period. They lost 8 IQ points. That’s 
going from the 50th percentile to the 29th. That’s a pretty big 
drop. In fact, other people in their environment were able to 
notice it. It was actually discernible. People could notice the 
people who had smoked during adolescence even 25 years 
later; their attention and memory were poorer, even when 
they had stopped for a year or more. 
Potency has increased. 
 
What’s also interesting, regarding underage use, which is 
a particularly worrisome issue with potential legalization, 
is these are the states where you see marijuana, medical 
marijuana, and legalized recreational use. You see the green 
and the dark green. Now I’m going to show you the rates of 
past month use of marijuana in 12 to 17 year olds. 
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You see that? You see the relationship? The heavier colors, 
the red colors are the heavier rates of use among teenagers. 
So I would say a moderate to strong correlation between 
medicalization and legalization and higher rates of use in 
teenagers.
 
This is perception of great risk. Again, there is exactly the 
same pattern among adolescents. Those living in states 
where it is medicalized or legalized, you see a strong 
correlation between that and a lower perception of harm. 
 
One of the other things from a public health and safety 
standpoint is edibles. Now we have concentrated forms of 
alcohol. We have hard liquor. We have beer. We have wine. 
We have different concentrations of alcohol. And we have the 
same for marijuana. 
 
One of the things we have seen is an increase in poisoning 
among kids as they have picked up gummy bears, candies and 
consumed them. In fact, exposure among 6-year olds in terms 
of poisoning has increased about 148% from 2006 to 2013, 
particularly in states where medical marijuana is available. 
 
As you might suspect, as we’ve seen with the opioid crisis, 
the more you have these sitting around in people’s medicine 
cabinets, the more likely people are to pick them up and 
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use them. The same seems to be also true with marijuana, 
too. The more you make it available, the more likely it is for 
someone to consume it and potentially have an adverse 
event. 
 
What have we learned about Colorado and Washington in 
terms of what’s happened there with legalization? 
 
We have seen, similar to medical marijuana states, an 
increase in emergency department visits. Again these are 
small numbers. You look at the bottom, n=10, there on the 
right, so these are very small numbers of people, but it’s going 
in the direction that we don’t want to see, but I would expect 
to see given higher availability. 
And the same after the legalization and commercialization of 
marijuana: We see increases in emergency department visits 
in Colorado related to acute intoxication.
 
  
Another worrying aspect of marijuana in particular is an 
association with psychosis. We know that exposure to 
cannabis, part of the pharmacodynamic effect of cannabis/
THC on the brain, is that it produces psychosis. 
 
At high doses, it can produce hallucinations, and it can also 
produce a residual psychotic spectrum illness. Sometimes 
this does not go away; we call this schizophrenia. Sometimes 
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it does go away after 6 months or 12 months. I’ve seen many 
cases that have been exposed to high potency marijuana who 
have had one or two years of psychotic spectrum illness and 
not schizophrenia, but nevertheless, it’s been very debilitating 
for individuals. There is a strong link with psychotic 
symptoms. 
We don’t really know what the true story is regarding 
schizophrenia, but there is an association there. About 
half the risk for schizophrenia is genetic, but it requires 
exposure to certain environmental conditions and certainly 
exposure to marijuana may increase the risk of the onset for 
schizophrenia. We need more research in that area.
The third thing I want to talk about is intoxication. 
Intoxication, of course, is another pathway, different from 
toxicity and different from addiction. You can smoke and get 
high with a packet of Doritos on your couch, and there’s not 
much of a consequence, but if you get in your car and drive, 
then there can be a consequence where you have to really pay 
attention and focus and respond quickly to things that  
are coming around the bend.
What we see with marijuana: It produces psychological 
impairment. It increases the risk of having an accident by 
about two times. There are many studies that have looked at 
this, and this is a quantitative review showing that because it 
produces impairment in reaction time, attention focus, etc., it 
produces accidents.
 
This is an interesting study that just came out looking at 
marijuana drugged driving and openness to driving while high, 
which was done in Colorado and Washington. Just published. 
What they found is that in this sample of roughly 865 folks, 
the past year driving under the influence of marijuana was 
44%, and prevalence within one hour of using marijuana five 
times in the past month was 24%. So it’s quite high when you 
look at a potential damage that lifelong harm that that can 
produce. 
  
This is also a study that recently came out in Colorado looking 
at trends in fatal motor vehicle crashes before and after 
commercialization.
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What we see over on the right hand side is an increase in 
Colorado after the commercialization of marijuana. There is 
also an association of medical marijuana with an increase in 
deaths, crashes related to marijuana, and testing positive  
for marijuana after the crash. Those on the other line below 
are the non-medical marijuana states.
 
In Washington State, there has also been an increase in 
drugged driving cases: about a 33% increase relative to the 
baseline. 
 
Drivers testing positive has gone up over time. 
What’s interesting is age. We see that young people are 
much more likely to drive under the influence. You can see 
here, between the ages of 16 and 25, 26 and 35—these are 
the highest rates. Young people are the ones who are smoking 
marijuana as well.
Just to finish up, when we think about legalization, there are 
pros and cons to each position. We think about the potential 
pros of legalization, and we would improve the quality control 
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of the product. That’s what happens when we legalize it. We 
can eradicate arrests due to possession and we can eradicate 
the black market. The bad guys get put out of business. 
Now we have control over the quality of production and 
distribution, and of course it can produce tax revenues. So this 
is one of the arguments for it. 
On the downside, there are public health and safety harms 
having to do with increased addiction, toxicity, neurotoxicity, 
and intoxication. Drugged driving. Accidents. Those will 
increase. We’ve seen increases in toxicity-related poisoning. 
We are likely to see that especially with edibles. 
And, of course, we have to consider the enforcement of 
legalization. As I mentioned, there are 3 million arrests for 
alcohol—that’s a legal drug—a year. We would reduce arrests 
for possession by 700,000, but we may replace that with 
arrests for violations of the legalization laws/regulations 
governing marijuana. 
Another thing to consider, of course, is productivity. One of 
the major contributors to the burden of disease, disability, 
and premature mortality related to alcohol and other drugs 
is lost productivity: People missing work or not working to 
their full potential because of the impact of their psychoactive 
substance on their cognitive functioning. With more people 
exposed, we are likely to see more lost days in terms of 
productivity.
With that I will stop and thank you very much for the 
invitation and your attention. I’ll take questions. Thank you.
Question anD answeR
audience:  What do you see is driving the effort to complete 
legalization? Is it commercial interest? Is it other recreational 
business? Given that all of the problems that you mentioned, 
what’s behind it?
John Kelly:  One is supply. One is demand. One is the 
corporate interest that is projected by 2020. If we were 
to follow the path of legalization, the marijuana industry 
would be $35 billion a year. That’s a lot of money. And 
these individuals want to legalize it like alcohol. This is their 
motto. This is in fact their name. Legalize marijuana like 
alcohol because the alcohol industry makes a lot of money 
from commercialization, so that’s what they would prefer. 
There’s going to be a lot of push to commercialize it and 
make big profits. There’s also a demand side, so there’s a lot 
of people who want to be able to smoke marijuana, and why 
should marijuana be illegal if alcohol is legal. So they make 
that argument. It’s a both a supply and a demand, I think, 
but there’s a lot of misinformation. As we all know, sitting 
here today, there’s a lot of misinformation, fuzziness, and 
muddying of the waters out there, so it’s hard to get any real 
reliable information on this topic, so that makes it tricky, too.
audience:  On the subject of actually [inaudible] market 
regulation, do we know what kind of substances are going to 
be [inaudible] United States [inaudible].
John Kelly: They’re kind of in that sweet spot of being 
regulated, like opioids. That’s a bad example right now, but 
there’s one, benzodiazepines, stimulants, like Adderall. These 
have potential for diversion and misuse because they produce 
effects that people like recreationally. But there is a sweet 
spot here in the middle. That’s what you’re alluding to. Those 
drugs would fit into that category, but we’ve seen a problem 
with overprescribing of opioids, which we’re going to hear 
about this afternoon. Again, it’s kind of ironic, isn’t it? On the 
one hand, we’re talking about an opioid crisis which is caused 
by excess availability. And then we’re talking about marijuana, 
and we want to increase availability, even though we know it 
causes similar issues. It doesn’t cause the kind of mortality 
that we see, direct drug-specific mortality, drug-induced 
mortality that we see with opioids. 
Nonetheless, it causes a lot of other problems that we’re 
going to have to contend with. It’s kind of ironic. We’re going 
to increase availability and give them access to marijuana, 
while we’re fighting right now to decrease availability of 
opioids. 
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But I think the sweet spot would be decriminalization. You 
look at Portugal. They have decriminalized the use of all 
drugs. Have not seen a great increase in drug use, if at all, by 
decriminalizing. That’s not legalizing. That’s decriminalizing 
any personal drug use. It’s still illegal to sell and distribute 
drugs, but it’s not illegal to consume them. That’s what we 
had under prohibition for alcohol actually. It wasn’t illegal 
under prohibition of alcohol to consume alcohol. It was illegal 
to sell, manufacture, and distribute alcohol. That was the 
amendment. But it, if you look at decriminalization, that’s the 
pretty good sweet spot right there in terms of reducing the 
overall harms of both commercialization and prohibition. 
Another way to go would be legalization with no advertising, 
state controlled monopoly, like New Hampshire does with 
alcohol. You have state run stores. People can get it. It’s not 
illegal, but it’s not being pushed in people’s faces. There are 
no targeting of vulnerable subgroups through advertising, and 
that could be a way that we could reduce harm, too. Still be 
legal, but it wouldn’t be the full-blown commercialization that 
we’ve seen with alcohol and tobacco and the related harms 
associated with that.
audience:  My question is in this statement, but you could 
speak on it a little bit with smoking of cigarettes when 
you had the 1960s and that push with cigarettes are bad. 
That knowledge was out there, but suddenly became more 
prevalent throughout the years. Some studies you’ve seen the 
rates of smoking cigarettes decline. Do you see something 
like that happening with marijuana eventually with the 
knowledge that particularly with younger people using it that 
there are detrimental effects? Do you see that eventually 
taking place?
John Kelly:  I think we can see that happening, if we went 
the path of legalization. Now we’ve got a cheaper product, 
quality controlled. Maybe with advertising, more people are 
going to use it. Your rates are going to go up. I’d be shocked 
if rates did not go up. Absolutely shocked. I’d bet my house 
that rates are going to go up. Rates of addiction are going to 
go up, rates of drugged driving, accidents. All of that will go 
up. After ten, twenty, thirty years, who knows? Maybe people 
will say maybe we need to put a lid on this. Maybe we need 
to change some of the policies, like we did with tobacco, 
and increase the price and make it less desirable and less 
available. I think we have learned some lessons from tobacco 
that we can apply to marijuana — and from alcohol that we 
could apply — if this went through in more and more states 
like Massachusetts. But my guess is yes, I think as we start to 
see more harm incurred — the casualties from addiction and 
intoxication and toxicities — that we might start to implement 
some of those lessons. One of the other arguments, of course, 
is let’s try this for a while and then we can go back, and we’ll 
go back and ban it again. How hard is that to do? We tried 
that right. It was called the 18th amendment. Ever try to make 
something illegal that’s been embedded in our culture that 
has tax stakes, tax embeddedness in it? In Colorado they’re 
using that tax for schools. 
audience:  I would say let’s see what happens in Colorado 
and we’ll decide five years from now. I think that’s better to 
[inaudible], but that’s not the reason I raised my hand. Did 
either of you hit on the [inaudible] marijuana just following 
up to your question, is a carcinogen that will cause like lung 
cancer, emphysema whereas you pointed out smoking has 
gone like this there’s a concerted national effort to drive down 
smoking rates and it’s worked. Does marijuana cause lung 
cancer? Will people die from lung cancer if they’re users?
John Kelly:  There aren’t too many studies, there aren’t too 
many long-term studies that have looked at this, but there 
are respiratory problems. Lung problems. Breathing problems 
with smoking marijuana. Less so with vaping. So if you’re 
vaping without any of the bad stuff being burned and inhaled, 
that can reduce the risk of respiratory problems.
stacy gruber:  There’s only been one study demonstrating 
that there isn’t a huge increase in lung cancer in folks that 
smoke marijuana, but again, they are pretty sparse and the 
one thing is that vapors and things like that are incredibly 
carcinogenic, so the idea is to move people to more safe ways 
of using.
audience:  So you talked about decriminalization as a sweet 
spot and one of the things that gets lost in the conversation 
is I do clinical work. A lot of people don’t know, I’m not a 
policy expert, but I believe in [inaudible] small amounts of 
possession under 20 grams of marijuana. For people who 
don’t know, that’s a daily use for quite a while. It’s quite a 
lot. So based on—is there any data out there or based on 
your expertise, why is decriminalization not good enough for 
people if it does seem to hit the sweet spot where we’re not 
increasing availability but we’re also not incarcerating people, 
and if it hits that public health sweet spot, why is that not 
good enough for some people?
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John Kelly:  I think part of it is that people don’t know the 
difference between decriminalization and legalization. In 
people’s minds, they think that’s the same thing. That’s why 
they think, we’re arresting all these people with marijuana 
and the war on drugs doesn’t work, therefore let’s legalize 
it. Really that’s an argument for decriminalization, which is 
not legalization. So I think a lot of people don’t understand 
the maybe subtle difference between decriminalization 
versus legalization, and then legalization with few restrictions 
or with many proscriptions, versus legalization with 
commercialization with few restriction. I think that’s part of 
it. People don’t know in the general public or they don’t even 
stop to think. I think that’s part of the problem. But when you 
look at a chart like this you think oh yeah, I didn’t really think 
about that. Right? Didn’t really think about that. What’s the 
scientific basis of medical marijuana? I didn’t really think 
about that. I just think that this is a really a good idea. By 
popular vote, we’ve made that legal. Not based on science but 
based on popular vote. Interesting.
audience:  I just want everybody in the room to know that 
I’ve been [a district attorney] since 1984. I can’t think of 
a single case in Boston where somebody went to jail for 
possessing marijuana in my entire career. In fact going back 
30 years, the state legislature passed a statute that says if 
you’re caught with possession of marijuana, it’s an automatic 
disposition of continued without a finding, which means 
if you keep your nose clean for a period of time, the case 
is dismissed. And in order to be convicted of trafficking in 
marijuana in Massachusetts, 50 pounds. You said 20—20 
grams is enough to keep you going for a month. How much 
is 50 pounds. Very few people even go to jail for that in 
Massachusetts. I just wanted you to know that.
John Kelly: And pretty much universally, that’s true. Pretty 
much across the board, but maybe down south and places 
in Texas, you might see more harsh penalties, but in general 
where there is decriminalization, hardly anybody will go to 
prison just for use or possession of a small amount. 
audience:  I have [inaudible] both of you mentioned the 
increase in drugged driving and I know from speaking with 
different legislators, one of the challenges is how do we know 
and how do we measure drugged driving the same way that 
we’re able to measure drunk driving and be able to prosecute 
correctly people who are driving [inaudible]?
John Kelly:  We don’t have a good way right now of 
measuring that. Roadside. And so this is a problem that we’re 
going to face: developing technology that can be immediately 
appraised and evaluated to see if someone is under the 
influence. The way that it’s been done is post hoc. After an 
accident, they’re taken in and taking a urine sample a blood 
sample a bit later.
audience:  Is there any evidence that legalization increases 
consumption?
John Kelly:  Yes. Oh yes. Again, price and availability are 
two big factors which will influence consumption. Every 
company knows that. Price and availability of their product. 
If you make something that produces euphoria and pleasant 
feelings like Oreo cookies or something like that, or marijuana, 
alcohol that people like the effect of. You make it cheaper. 
You make it available on the corner, legally you destigmatize 
it, and you will see increased use. That’s different from 
decriminalization. Right? And also it depends on, like I said, 
are you making it legal with full commercialization? Or 
are you making it legal and with non-commercialization? 
There’s a big difference there, as we’ve seen with tobacco 
and alcohol. There are certain restrictions governing alcohol 
and tobacco, but the alcohol industry spends $15 billion-$20 
billion a year on advertising. So they know advertising works. 
And it’s worth the investment if they spend that much money 
advertising. Think how much money they’re making based 
on the advertising. So commercialization really does increase 
consumption because it increases those profits.
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 The Highs and Lows of Relapse and Recovery 
in Opioid Use Disorder
 
by Kathleen M. palm Reed, ph.D.  
pOlicy Brief 
Opiate use Disorder (OuD) is a chronic, relapsing disorder with significant 
mortality, morbidity, and disability. Over 2.6 million americans are currently 
living with an opioid use disorder.1 high relapse rates2 and rapidly increasing 
numbers of overdose deaths3 highlight the urgency of the opioid crisis.
Early stages of treatment, when relapse and overdose rates are highest,4, 5 are a critical period for setting 
up a successful recovery. Early lapse is predictive of full-blown relapse and may lead to treatment dropout.6 
Conversely, early abstinence in the first few weeks of treatment is predictive of long-term abstinence.7 Being 
younger and unemployed increase risk of early relapse.8 Additional risk factors for early relapse include co-
occurring mental health conditions, use of other illicit substances, and chronic pain. 
Fortunately, there are a number of relapse prevention and treatment options that improve chances for 
a successful recovery. Those who receive ongoing supportive counseling, medication-assisted treatment,9 
greater drug-free social support,10 and who actively participate in AA/NA have better long-term outcomes.11 
Further, having positive expectations about treatment success and greater commitment to abstinence12 
influence treatment engagement and long-term abstinence. Unfortunately, barriers such as stigma may 
defeat any positive expectations of recovery and, ultimately, lead to treatment dropout.
stigMa as a RoaDbloCK to ReCoVeRY 
While public perceptions of OUD are changing, there continues to be a prevailing view that substance 
use is a moral failing. This stigma is apparent in the larger culture, but also among treatment staff and those 
suffering with OUD themselves. 
Institutionalized stigma impacts treatment retention and engagement, and effective care.13 OUD 
treatment is segregated from the rest of health care in practice and location, limiting the opportunity 
for communication between OUD and other health care providers, and decreasing accessibility to OUD 
treatment clinics. Integration of methadone maintenance treatment in primary care settings has shown 
greater treatment retention compared to stand alone clinics.14
Another source of stigma comes from treatment staff, who may regard individuals with OUD as 
untrustworthy and dangerous.15 Greater stigma and rejection by treatment staff is particularly reported 
by patients with more prior episodes of treatment, intravenous drug use, and co-occurring mental health 
conditions.16 Unfortunately, similar stigmatizing attitudes are also  present in self-help groups, with many  
of those in recovery reporting that they do not disclose their participation in methadone maintenance 
treatment due to fear of stigma and rejection.17
Shame and internalized stigma associated with opiate use can trigger relapse and also serve as a  
barrier to seeking help. Among adolescents with OUD, two of the most frequently cited reasons for not 
seeking treatment are “didn’t want others to find out,” and “treatment might cause neighbors to have  
negative opinions.”18
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poliCY ReCoMMenDations 
•   The first few months after treatment are a high risk period for relapse. We need greater efforts to facilitate 
aftercare services and exposure to drug-free support networks. Vocational services may mitigate risk for  
early relapse.
•   Peer recovery and 12-Step programs are beneficial, and may offer sustainable sources of support for those in 
recovery. Specific recommendations by physicians to pursue these programs may foster greater participation. 
•   Consideration should be given to relocating drug treatment services to mainstream health centers that 
address both substance use disorder and underlying medical and/or behavioral health issues.
•   Improved training and support, and increasing the number of treatment providers, may reduce burnout and 
increase compassion among treatment staff, thereby decreasing stigmatizing attitudes.
•   Educational campaigns aimed at changing attitudes and perceptions of OUD and treatment may reduce 
stigma. Further, educating families and schools on how to discuss substance abuse and treatment options 
can facilitate help-seeking.
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Today I’m going to talk to you about opioid use disorders. 
When I talk about opioids, I’m referring to heroin and 
other opiate prescription medications such as OxyContin, 
oxycodone, hydrocodone, and others that fit that group.
I’d like to give you a brief overview of trends that we’ve seen 
in terms of opioid use disorder, with particular  
focus on the relapse and recovery for individuals who  
are struggling with opioid use disorder.
 
So, before talking too much about relapse and recovery, I’m 
going to talk to you a little bit about why people become 
addicted in the first place. This is usually the first question 
that my students ask me when I’m talking to them about 
substance use disorders. As many of our speakers have 
already alluded to in our talks this morning is, it’s complex. 
There could be a number of historical, biological, and 
environmental factors that increase one’s risk for becoming 
addicted to a substance.
Additionally, there could be factors associated with the 
drug itself. All of these things interact with each other to 
increase one’s risk for addiction. There’s no one defined route 
that leads one to addiction. People become addicted for 
different reasons. Similarly, there’s no one simple answer for 
addressing substance use disorders, specifically opioid use 
disorder.
So, interventions and policies that we adopt to prevent 
substance use disorder, and to improve our rates of recovery 
for opioid use disorder, need to be multi-pronged, addressing 
both of these individual and these environmental factors.
It’s estimated that approximately 2.6 million Americans are 
currently living with opioid use disorder. What’s become 
the opioid epidemic has been fueled by a number of things; 
including an increase in use and abuse of prescription opiate 
medications and increase in use of heroin. Heroin has become 
more available and cheaper than prescription opiates, and 
so more people are using heroin. It has gained particular 
attention related to the increase number of overdose deaths.
 
Looking more closely at the overdose-related deaths across 
the country, heroin-related deaths have quadrupled since 
2000, and have continued to be on the rise.
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If we were to translate these figures into what we’re seeing 
on the ground every day, if we look at opiate-overdose deaths 
related to opiate medications alone, we could estimate 
there are about 46 deaths per day that are associated with 
overdose-related deaths.
 
 
This data is mirrored in what we are seeing in Massachusetts, 
as well. So there has been a steady increase in the rates of 
opioid-related deaths since 2000, particularly in the past five 
years. The rates in 2015 are still being finalized, but they’re 
similar to what we’ve seen in 2014.
So the deaths — the accidental deaths related to opioid 
overdose, are now surpassing what we see in terms of car 
accidents.
So the next logical question is, why are we seeing this 
increase in overdose deaths? There are a number of possible 
factors that might be contributing to this. First, there’s an 
overall increase in the number of heroin users. It’s more 
available and cheaper, and so more people are using it.
There has also been an increase in the transition from 
prescription opiate use and abuse to heroin. In some ways, 
prescription opiates have become more expensive and less 
available in recent years, and so some people are turning 
to heroin as an alternative. In particular, between 2010 and 
2014, the Northeast region of the country saw the greatest 
transition from prescription opiate use to heroin use.
Another factor that contributes to the rates of overdose 
deaths could be the varying composition and the 
concentration of heroin that people are using. So, if people 
were using prescription opiates before, there’s a known 
amount of opiates that are in there. With heroin, you don’t 
know what you’re getting. There are varying doses and 
concentrations in it, and plus, there could be additional 
adulterants that are included in the heroin.
Fentanyl, for example, is one that we’ve heard about on the 
news recently, which can be lethal. And people don’t know 
what it is that they’re injecting.
Another reason why we’ve been seeing this increase in 
overdose-related deaths is that people, after they’ve had a 
period of abstinence, have a lower tolerance. If after a period 
of abstinence from being in treatment or being incarcerated, 
they relapse and go back to the level of use that they had 
before they had the period of abstinence, then they’re at 
higher risk for overdose.
 
I want to spend some time today really focusing on this 
period of relapse—this phenomenon of relapse. There has 
been a lot of discussion about the prevention of opioid use, in 
general, which is very important.
But it’s also important to understand what it’s like for people 
who are already struggling with opioid use disorder, and 
to understand the phenomenon of relapse and relapse 
prevention.
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Over time, our understanding of what addiction is has 
changed, such that we’ve been understanding it more 
as a chronic and relapsing disease. We’ve come to this 
acknowledgement after realizing that relapse is common, 
with rates of lapsed opiate use from treatment-seeking 
individuals ranging from 60%-90% after treatment.
Relapse can happen at any time during recovery. It can 
happen after one year of being abstinent. It can happen after 
five years. It can happen after ten years, at any point — and it 
may take an average of nine years following someone’s first 
intervention before they can have a full year of abstinence. So, 
we’ve come to understand recovery as a process because of 
this. Someone may experience multiple episodes of this use, 
abstinence, relapse, and treatment multiple times before they 
can achieve a full remission.
 
If we’re thinking about substance use disorders or opioid use 
disorders, as chronic relapsing conditions, you might compare 
them to other chronic illnesses that we know something 
about. For example, other chronic illnesses are Type 1 
Diabetes, asthma, and hypertension; and with those chronic 
illnesses, we also see high rates of relapse, affecting over half 
of those who are treatment-seeking.
 
Now this is hypothetical data; this isn’t an actual study, but 
unlike other chronic illnesses, individuals who are struggling 
with substance use disorders are sometimes expected to 
be fixed after they have acute treatment. They go through 
detoxification, and that’s meant to cure them. Right? We 
shouldn’t expect any kind of relapse.
If we had that same kind of picture with someone who is 
struggling with hypertension, for example, and someone was 
really having a difficult time  — they went into treatment, 
they were discharged from treatment, and there was nothing 
else that was done for them — then we wouldn’t be terribly 
surprised if they relapsed and needed to be readmitted to the 
hospital.
Yet, we have this expectation with people who are struggling 
with substance use disorders, that they suddenly are cured 
from this. It’s estimated that 31%-50% of opiate-dependent 
patients will relapse within the first two weeks after 
treatment. Not surprising if they’re just expected to go out 
and try to deal with this on their own.
So, like other chronic illnesses, we should consider how we 
could best address the long-term maintenance of opioid use 
disorders, rather than just focusing on managing acute crises.
Researchers have been trying to understand what increases 
the likelihood of relapse. There have been a number of ways 
that researchers have tried to look at this. One way is they’ve 
interviewed people who have relapsed already and asked 
them to think back on what led to a previous relapse and to 
tell us more about that.
Another way that we’ve been trying to assess it is when 
people come in, we collect a lot of different information, do 
a lot of the clinical assessments that have been mentioned 
earlier, and follow them over time, to see after treatment, 
which one of those factors that we assessed beforehand 
actually predicts how well someone does afterwards, and 
what is predictive of early relapse.
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When we ask patients what they said led to relapse, they 
indicate a number of things. Probably some of the most 
commonly reported reasons are that they were exposed 
to triggers in some way; they might go back to their home 
environment or back to being with their friends who were 
using with them before. That might trigger a relapse.
There might be some sort of stressful life events, which 
could be negative; people also report positive events as 
being triggering and leading to relapse. Occasionally, people 
describe craving and physical discomfort that’s associated 
with withdrawal.
Most often, people describe negative emotions that they 
experienced as triggering of relapse experiences, and 
sometimes it’s a combination of positive and negative 
emotions.
This is one study that we’re wrapping up right now in my 
lab — Jessica Armstrong is finishing up her dissertation on 
this. She interviewed about 80 individuals in detox and asked 
them what they thought was going on that led up to their 
relapse experience.
I have a few quotes of what they reported was going on. One 
person says, “I feel a lot of guilt. And then at the same time, 
you feel excited because you’re going to get your love back; 
the boy, you know, or the girl. And you feel ashamed. You feel 
sneaky. You feel like you’re getting over and you’re really not. 
You’re only hurting yourself. And sometimes, you’re almost 
happy, because you’re back in your element again.”
Another person describes a similar mix of positive and 
negative emotions. They say, “I’ll get like, big rushes of 
excitement before I know I’m going to do it, and then maybe 
like, even waves of nausea, because I know it’s a bad decision, 
and I just can’t stop myself. Once the seed has been planted, 
it’s planted, and it doesn’t get uprooted. It doesn’t come out. 
It goes until it dies,” or until the person uses.
Through many of these interviews, we’ve also noticed that 
people know they’re going to relapse before they actually 
relapse, and sometimes they have it planned out. You can 
see that they pull out of different types of support services 
that might have been helpful in maintaining their abstinence. 
So what that can indicate is that if they know that they’re 
planning this, this might be an opportunity for treatment 
providers to intervene if we can recognize the signs that 
someone is starting to make a plan to relapse. 
 
By looking at the research that has followed patients over 
time to see what factors really predict how soon and whether 
or not someone is going to relapse, we’ve identified several 
factors.
One is — and this is something that’s come up in some of the 
talks earlier today — the earlier someone starts, the more 
difficult it is to stop, and the more likely it is that they’re going 
to relapse. So, making sure that we address that the age of 
onset of substance use disorders is important in marijuana. 
It’s also important in terms of individual’s introduction to 
opioids.
We know that early recovery is a stage in treatment. The early 
stages of treatment are a time when relapse and overdose 
rates are high; this is an important time that we address. We 
also know that early abstinence is also predictive of long-term 
abstinence.
So this accumulating data is showing that there’s something 
about the first several weeks, the first several months after 
someone has a period of abstinence through treatment; 
mostly that it’s important that we provide supports during 
that time.
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We also know that co-occurring health problems—whether 
they be psychiatric, whether there’s a trauma history, whether 
there’s chronic pain—that these are also risk factors for 
relapse. I do want to mention that there is some concern out 
there that chronic pain is a risk for substance use disorders. 
While some people with chronic pain do experience opioid 
disorders, that chronic pain in and of itself doesn’t mean that 
someone is going to have an opioid use disorder.
However, if you have an opioid use disorder and chronic 
pain, it could be a risk factor for relapse because once they 
don’t have the opiate anymore, they don’t know how to really 
address their pain.
Numerous studies have also found that unemployment  
is a risk factor for relapse. So people who have a steady job 
are more likely to be able to maintain their abstinence. Then 
as I mentioned before, what the patients said was a trigger for 
relapse is just being back in the same environments that they 
were before they were abstinent. Those environments can be 
triggering.
Now we know that these factors are triggers for relapse—are 
predictive of relapse. We know a little bit about what types 
of interventions can be helpful, but there’s a lot more that we 
can learn about it.
In terms of addressing the age of initiation, we can do our 
best in terms of education and awareness campaigns, so 
that we can keep our youth from becoming addicted to these 
substances. Then also, we can limit the availability of these 
substances so they don’t have access to get started with 
them in the first place.
In terms of addressing early recovery as a risk period for 
relapse? There has been a lot of data showing that ongoing 
support, participation in AA and NA, and other peer-recovery 
networks, has been really helpful in helping people achieve 
positive, long-term outcomes.
There’s also been recent data that individuals with opioid 
use disorder may benefit, even more than other people 
with substance use disorders, from long-term residential 
treatment, in helping them maintain their abstinence and 
recover.
So, it could be that when they are in a sober environment, 
they can really benefit from that, partially because they have 
the ongoing drug-free social support and they’re not exposed 
to the triggers that might be increasing their risk for relapse.
There are a number of evidence-based treatments that have 
come out that try to address the whole person, and not just 
their substance use disorders. So, there are treatments out 
there that are addressing trauma and trauma reactions that 
people might be experiencing, that can help them learn 
additional pain management strategies, whether they be 
psychosocial or pharmacological. And then also, helping 
people learn other strategies to deal with anxiety, depression, 
or other psychiatric symptoms that might increase their 
risk for relapse. Vocational services have been discussed 
as a potential addition to existing treatment services, 
given that unemployment is such a risk factor for relapse. 
Adding vocational services to existing treatments might be 
something important to explore.
As I mentioned, a drug-free social support — attendance 
at AA and NA or other peer-recovery networks — could be 
helpful with decreasing exposure to triggers.
One factor that was not on that list that I want to spend a 
little time talking about is stigma. So, stigma can be another 
risk factor for relapse, and it can be a major roadblock in the 
process of recovery.
Individuals can experience stigma through the public’s 
perception, through our healthcare system, from healthcare 
providers themselves, and then they may internalize some of 
this stigma. This experience of stigma can really impact the 
patient in terms of just how they’re feeling overall, but also 
limit their engagement in treatment – in their willingness to 
stay in treatment — so, treatment retention and their overall 
health.
It could also lead to chronic stress, and keep people from 
asking for help in the first place if they’re struggling, or if they 
know that they’re about to relapse. If they’re experiencing 
stigma, then they might be less likely to ask for help.
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There have been a number of initiatives that have tried to 
address these different levels of stigma, so education and 
awareness campaigns can be useful. In fact, there’s one —  
I don’t know if folks have seen it yet, but it’s the “End the 
Stigma of Addiction” campaign that has been launched by 
the State of Massachusetts.
These types of campaigns can be useful, but research 
suggests that they may also be insufficient. When looking at 
actual stigma reduction, research has shown that there’s been 
minimal impact on actual stigma reduction.
The strongest evidence is found for interventions that focus 
on creating more personal contact between the stigmatizers 
and the stigmatized groups in a positive context. So, we 
should have these educational campaigns, but know that 
they’re not going to be the silver bullet that addresses stigma 
in the public eye.
Individuals with opioid use disorder also describe 
institutionalized stigma. So, within the healthcare system, 
they experience a feeling of discrimination. First, there could 
be a lack of coordinated care between addiction treatment 
services and primary care providers, such that primary care 
providers might not know that someone is in addiction 
treatment and might be fearful of even mentioning it.
We talked about how unemployment can be a risk factor 
for relapse, but if someone is on methadone that means 
that they have to go and get it daily. It sometimes could be 
a lengthy task. There might be limited times where they can 
actually go to collect their methadone, and so it’s hard to 
sustain full-time employment with some jobs when you also 
have to add that into your schedule.
There can also be a lack of privacy when going to collect the 
methadone. Sometimes in our healthcare systems, in our 
addiction treatment services, there are urine screens to test 
for whether or not someone is using; they’re used to catch 
someone doing something wrong and to throw them out of 
treatment.
Instead, it might be useful to think of it as a teachable 
opportunity, especially given we know that relapse is a part of 
the illness. It could be expected that someone can relapse at 
some point, and so rather than thinking of it as catching them 
doing something, using it as an opportunity to teach them 
something different and get them the help they need. 
There has been a lot of talk of making sure that individuals 
with opioid use disorder get access to care, but one thing 
that people might not know is that there has been research 
examining the level of formal training that physicians get, 
that clinicians get, that social workers get, in substance use 
disorder treatment. It’s really discouraging because not that 
many programs actually offer that level of formal education. 
So, well-intended treatment providers might not understand 
exactly what the person is dealing with.
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Further, our language about substance use disorders can 
be stigmatizing. There have been some studies that have 
looked at laypeople’s and professionals’ reactions to labels 
of substance abuser versus a person with a substance use 
disorder. People’s reactions to a substance abuser: “Well, this 
person needs some sort of punishment.” However, if they saw 
a vignette about a person who was described as a person 
with a substance use disorder, there’s more of an inclination 
to get this person clinical intervention and to help this person.
So, how we describe people affects our response to them. 
Healthcare providers and researchers, too, should continue 
to think about the language we’re using to describe the 
phenomenon we’re talking about, and the experiences that 
people are dealing with. We also describe urine screens as 
clean versus dirty. These might seem like subtle changes in 
our language, but it has an impact on the people that we’re 
working with.
There is a lack of education and a lack of understanding that 
opioid use disorder is a chronic relapsing disorder. This is why 
people keep coming back into treatment. It can really lead 
to a lack of trust and feelings of burnout amongst treatment 
staff, and eventually lead to internalized stigma.
 
It’s not surprising given these different levels of stigma, that 
people with opioid use disorder might internalize this. This 
is, again, the same study that I was talking about earlier. This 
person’s quote really exemplifies some of this internalized 
stigma and what it might look like for a person who’s 
struggling with this.
This person says, “I’m not happy with myself, that I’m back 
again. But yet, I’m grateful to be back. I’m very disappointed 
with my choices and my actions. If somebody put me down 
the way I put my own self down and remind myself of all the 
things I’ve done, that’s like a tape player in my head. ‘Ugh, I 
can’t believe you did that. I can’t believe you did that again. 
What’s wrong with you?’”
So this internalized stigma is associated with poor mental 
health and a greater risk for relapse.
On top of that, the experiences of stigma for minorities 
and the poor can be even worse, with some individuals in 
treatment having to depend on other patients to translate 
their sessions for them, and the poor having limited access  
to state-of-the-art treatment.
So, what could be some possible policy implications  
of what I’ve discussed today? One is that it’s important to 
really focus on that period of early recovery and make sure 
there are appropriate aftercare services so that we’re working 
on the maintenance of the opioid use disorder.
There’s been a lot of promise looking at drug-free support 
networks, so encouraging participation in AA and NA and 
other peer-recovery networks. In fact, some people have 
discussed asking physicians, nurses, and clinicians to make 
specific recommendations to patients to pursue peer-support 
programs.
In terms of addressing institutionalized stigma? Some 
researchers suggest that it might be relocating drug 
treatment services to mainstream health centers, so that 
they’re not so divided. Improving training and support of 
healthcare providers to try to limit burnout and give them 
more education about what substance use disorders are and 
what state-of-the-art treatments are. And then, increasing 
the overall number of treatment providers that are out there.
Education campaigns are also important in increasing our 
awareness and knowledge about opioid use disorder, with 
the caveat that education campaigns alone are probably not 
going to be the silver bullet that’ll address any public negative 
perceptions of opioid disorders.
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Question anD answeR
audience:  You mentioned that the [inaudible] time  
in a recovery home or — what do you mean by a long? In 
terms of [inaudible] two weeks? I think that’s what the 
current is in time, six months, or a year? Like, what’s the 
research show on that?
palm Reed:  I don’t know if it’s looked at, the exact length 
of time, but just more is better. We need to find out exactly 
what that kind of sweet spot is. We’re not exactly sure on 
that. That data is hot off the presses really. So, we need to 
find out what that is exactly.
audience:  What’s known about the relationship between 
the population that develops opioid use disorder and their 
prior use of say alcohol? Typically, the substantial proportion 
of the opioid abuse population also have a problem with 
abusing alcohol prior to becoming users of opioid?
palm Reed:  There’s a lot of poly-substance use. People 
who use a lot of different substances, and some people do 
start out with alcohol, with marijuana, but it’s not the only 
pathway to opiate use.
You hear in talking to a lot of individuals that sometimes 
they weren’t using alcohol, but they might have started 
getting hooked on opiates, specifically after surgery. Or 
even — I’ve heard people talk about in high schools, people 
knowing when everyone’s wisdom teeth are going to be 
taken out. So it might start there — where alcohol might 
have been used, it might now be pills. It might be the thing 
to share opiate pills instead.
So sometimes, but there’s not any kind of set, gateway type 
of drug that gets into opiates. So some people start directly 
with opiates.
audience:  [Inaudible].
palm Reed:  So do we want to completely eliminate stigma 
because there’s some kind of social control and utility to 
that in some way? There’s been some argument about that 
for addressing stigma because of that reason, which might 
prevent opioid use disorder, not for everyone. But it’s still not 
helping the people who are already struggling with an opioid 
use disorder and keeping them from seeking help.
So, it’s both, you know? It’s important to prevent opioid use, 
and also, we need to think about the impact of people who 
are already struggling.
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 Addiction, Overdose, Suicide:  
Facts You Need to Know about Treating 
Opioid Use Disorder
 
by Hilary Connery, M.D., ph.D.
pOlicy Brief 
Opioid misuse and addiction have increased severely during the past decade. 
Death rates associated with heroin and prescription opioid use are rising 
rapidly, despite efforts to control opioid availability and distribute life-saving 
emergency medication. prevention education and widespread access to quality, 
evidence-based treatments are needed now to stem the tide of this tragic, 
national epidemic.
out of ContRol: wHen opioiD use beCoMes opioiD use DisoRDeR
Naturally-occurring opioids (e.g., morphine) and man-made synthetics (e.g., painkillers such as oxycodone 
and hydrocodone) have been used successfully to treat pain, cough, diarrhea, and mental distress associated 
with physical injury and illness. Opioids are potent sedatives and in high dose can shut down the part of the brain 
in charge of regular breathing. Thus, there is always some risk associated with opioid use, especially in those with 
other risk factors for sedation or compromised respiration (e.g., pneumonia or other lung disease, use of other 
sedating medications, or alcohol use). 
Some people who are sensitive to the pleasurable effects of opioids have additional risks for taking more 
than prescribed or using opioids routinely to cope with stress. When this happens, repeated misuse can lead to 
patterns of addiction, with too much time spent seeking and using opioids, and too little time spent in normal 
life activities. This is referred to as opioid use disorder, and for many, the addiction cycle includes a need to keep 
taking opioids in order to avoid feeling sick (opioid withdrawal syndrome). 
It is also important to know that anyone chronically exposed to opioids will develop physical dependence 
and increased tolerance to the effects of prescribed opioids, even if they don’t develop addiction. Sometimes 
they will require higher opioid dosing to achieve the same effect, which presents more risk for sedation, reduced 
breathing, and overdose death.
tReatMents pRoVen to ReDuCe opioiD Misuse anD pRobleMs of aDDiCtion
Medical treatments proven to reduce opioid misuse begin with a careful assessment of the need for opioid 
prescribing, and limiting unnecessary exposure to opioids for medical conditions that may be successfully 
treated with less risky medical approaches. 
In the case of people presenting with opioid use disorder with physical dependence, three FDA-approved 
medications targeting brain opioid receptors will double the chance of good outcomes when added to evidence-
based psychosocial treatments for opioid use disorder (individual and group therapy, peer support such as 
Narcotics Anonymous and SMART Recovery). These medications include methadone and buprenorphine, 
which activate brain opioid receptors, reducing opioid craving and withdrawal; and extended-release naltrexone, 
which blocks brain opioid receptors and thereby prevents the pleasurable effects of illicit opioid use.
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In addition, people with opioid use disorder have high rates of co-occurring depression and suicidal thoughts and 
behaviors. Screening and providing evidence-based treatment for depression and suicide prevention is recommended 
for all people with opioid use disorder.
Can we pReVent opioiD oVeRDose DeatHs?
Controlled clinical trials and observational clinical data demonstrate that opioid overdose deaths are reduced in 
people with opioid use disorder who participate actively in a medication-assisted, evidence-based treatment. 
There is also evidence that the rapid administration of intranasal naloxone will reverse an opioid overdose 
death occurring in the community, and dissemination of easy-to-use kits to drug users, families, clinicians and first 
responders is indicated. Keep in mind that this approach is not treatment, but a life-saving intervention similar to 
cardiac defibrillation for heart attack. A person will not experience reduced risk following naloxone rescue unless that 
person engages in evidence-based treatment.
Educating patients on the risks associated with opioid use, screening for suicidality prior to prescribing opioids, 
and outlining procedures for safe storage and disposal of opioid medications will reduce unintended opioid exposures 
and overdose deaths.
opioiD use anD tHe faMilY: safetY fiRst, ConneCtion seConD
Families struggle with behavioral patterns associated with illicit substance use, such as personality changes, 
lying, stealing to support a habit, and otherwise unreliable behavior that is out of character and a symptom of active 
addiction. It is important that families have adequate options for receiving education and support about opioid use 
disorder, and that they understand how loved ones under the influence are chemically “disconnected” from normal 
relational attachments. 
Families need to be taught that safety is the priority in managing loved ones with active opioid use disorder, 
both their own safety and that of a loved one with opioid use disorder. Family connections may be weakened in 
the addiction cycle, and often are not a strong enough incentive for a loved one with opioid use disorder to enter 
treatment. 
CRAFT (community reinforcement and family training) is an evidence-based strategy for family members to 
help engage a loved one in treatment. Once the recovery process is occurring, family connections will strengthen or 
be repaired if all members are supportively engaged in the treatment process. Families are thus advised to consider 
safety as the first priority, and family repair work as a next priority integrated within the recovery treatment process.
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It’s a pleasure to be here. Before I start, I will tell you  
I’m keeping this presentation intentionally brief. It’s the end 
of the day, and there are a couple of points that I just want to 
make sure people have some basic knowledge about.
I did want to comment on that last question about stigma, 
only to point out that there is no other chronic medical illness 
where we use a negative stigma as a prevention strategy, and 
I don’t think we should be thinking about mental health or 
substance use any differently. 
 
 
So I don’t have any conflicts of interest or disclosures to 
make.
 
Bottom line I want you to take home is that treatment works, 
and we’re going to talk about medication-assisted treatment.
My main objectives are for you to understand in basic terms 
why we recommend medications to patients with opioid  
use disorder. Also, to understand that the overdose epidemic 
is more complicated than just addiction and accidental 
overdose. That mental health comorbidity is significant, and 
there is also good data to show that self-harm and suicide 
contribute much more significantly than you’re hearing in  
the public dialogue. I would like to raise more awareness 
around that.
Then finally, to talk about what families are worried about 
and the kinds of things that we know help them in terms of 
supporting loved ones in their recovery.
 
So, let’s start with the myth that’s been around for going on 
half a century. Every time I hear somebody say, “Aren’t we 
just replacing a drug with a drug?” I think to myself, “Really? 
Are we still having this conversation? How much science, and 
how much medical evidence do we need before we’re going 
to stop this conversation?”
 
So, if you take a look at this slide, it’s representing x-ray 
crystallography of the protein structure of the mu-opioid 
receptor in the brain. On the left side is a picture of what it 
looks like — looking front on — and that line in the middle 
there suggests that you have a neuron, or brain cell, that sits 
half on the outside and half on the inside.
transcript Of Dr. cOnnery’s talK 
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The way that protein receptors work is that when you have 
something that binds to them and activates them — in this 
case, we’re talking about an opioid — it binds to the outside 
of the cell, changes the shape of the receptor, and then the 
inside part of the protein has cellular activation. Okay?  
So that’s how it works.
I’ve shown you where medications bind; that would be the  
outside of the cell. Essentially, I always feel like we’re so  
fortunate when we treat opioid use disorder, that we 
understand that this receptor is destabilized in this illness.  
Because if we understand the site of where the destabilization 
is, we can actually develop — and we have developed —  
effective targeted medication treatments for that.
So this is what you need to know: The mu-opioid receptor in 
the brain is the site of the three FDA-approved medications 
that are demonstrated to be effective in treating opioid use 
disorder and helping people to get into recovery.
 
How do they work? We have two categories. One category 
blocks activation entirely at the receptor. When we talk about 
this, we’re talking about naltrexone, and in the case of opioid 
use disorder, preferably extended release naltrexone, which 
is also known by the trade name Vivitrol. Or we’re talking 
about naloxone, known by the trade name of Narcan, which 
is the emergency rescue. Both of these medications bind to 
that binding site, and they basically cap off the receptor; no 
activity can happen. That’s how they work.
So, if you’re talking about naloxone rescue, you are talking 
about something that rapidly displaces the activating opioid 
from the receptor and puts the person into an immediate 
withdrawal state, which is horrifically painful to the person 
who’s experiencing it, but it saves their life.
If you’re talking about medication treatment for somebody 
who’s coming into recovery, essentially what you do is have 
the person stop using opioids for a long enough period of 
time that then they can start taking the naltrexone treatment, 
which just seals off the receptor. In doing so, if during the 
course of their recovery, they have a bad day, and they use, 
nothing happens. They don’t get high. Essentially, they have 
an opportunity to say, “That didn’t work, and I didn’t want 
to do it in the first place; I was just having a bad day.” So it 
preserves them in recovery.
The second category activates the receptor. These would be 
buprenorphine, also known by the trade name of Suboxone, 
or methadone maintenance. The way that these work is that 
they bind to the receptor and they activate the receptor in a 
controlled fashion.
So somebody who is in recovery now takes a medication 
that’s prescribed at a very precise dose, and is monitored 
very carefully, and has a steady state effect, so that they’re 
not getting high; there is no euphoria. Essentially, they’re 
comfortable and able to get on with paying attention to all 
of the lifestyle changes that need to happen when you’re 
entering into recovery.
All three of these types of medications are really effective in 
treatment. And of course, we know that intranasal naloxone 
is saving many lives in the state of Massachusetts and across 
the country, for those who are in an overdose state.
When you look at the controlled clinical studies, the other 
thing about the FDA-approved medications is that for all 
three of them, the evidence shows that patients who add 
medications to the psychosocial treatment have doubled the 
chance of actually sustaining an opioid-free outcome. At least 
double the chance. In some studies, you’re looking at a six-
fold improvement.
So, these are effective. Medications without the mental health 
treatments attached to it, without an attempt to change your 
lifestyle, without peer support — medications alone won’t 
work.
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We know this. Why do we know this? Because there’s 
diversion. So, a lot of people in the community are using 
diverted buprenorphine, not in recovery. If it worked all by 
itself, you wouldn’t need people like me running clinics. 
People would just figure out how to get it, and they’d be 
better. They don’t work without all the supports.
The other issue: People argue, “What about those who don’t 
need a medication to get clean and sober?” The problem is 
what we know from clinical studies is that it’s a minority of 
people who come in for treatment, are detoxified, and do not 
have a relapse episode. 
Some people can do it. But from the medical perspective, 
we have no way of differentiating who’s going to be able to 
successfully enter a sustained recovery without a medication. 
Because we can’t tell that — and the data is such that it’s 
probably about 5% — and because the majority of people will 
do much better with a stabilization period with medication, 
we recommend it universally.
What I would hope in the future is that we might be able to 
identify the subset through a blood test or a brain scan or 
something like that, and then be able to more precisely target 
not just who needs medication, or who can do it without 
medication, but beyond that, which medication is right for this 
person? We have three medications because not everybody 
responds well to any single one of them, and we need to have 
these options.
 
Myth number 2 is that, “Aren’t we contributing to overdose 
deaths by prescribing Suboxone and methadone?” The 
answer to that is simply: it’s true if these medications are 
used illicitly, not so under a monitored treatment. Somebody 
gets it on the street. Somebody gets it from their dealer. Yes, 
we have data that these medications are involved in overdose 
deaths, but they’re being used in the wrong way. People are 
accessing them not in treatment.
 
The truth is that when people are taking them in a treatment 
setting, overdose deaths are reduced. So, we shouldn’t 
be afraid that treating people appropriately with these 
medications is going to increase overdose. It doesn’t. The 
data is totally against that. It decreases overdose.
We should be concerned that when these medications get 
diverted into the community and people are doing who knows 
what with them, that they show up in forensic reports as part 
of a tragic overdose death.
Did anybody see President Obama yesterday in the opioid 
summit — the National Opioid Summit? Nobody? I’m 
surprised. Well, it was great. It was really terrific. A lot of 
great stuff was talked about, and I’m encouraged that we 
have some of the most comprehensive dialogue around what 
we need to stop this epidemic. It’s not just about medication, 
and it’s not just about treatment, and it’s not just intranasal 
naloxone, but a full-on community effort.
Although, one thing that I noticed is that we’re still using this 
terminology of overdose accidents. It’s really quite inaccurate 
if you think about what an accident is. An accident assumes 
that the person’s not really aware of risk.
So when you think of opioid overdoses, the only real accidents 
that I know of are the ones where there’s a pediatric exposure. 
Somebody leaves their opioids out, and a child who knows 
nothing about the pills, what they do, or what the risk is, takes 
the pills and has an accidental overdose.
For those who are using opioids, you ask any of them, and 
they’ll be the first to tell you, “I know this could kill me.  
I don’t think it’s going to, but I know this could kill me.” So, 
right then and there, if somebody’s engaging in a self-harm 
behavior that they know could potentially kill them, it’s not 
quite accurate to label a death like that as purely an accident. 
There was some risk assessment involved.
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The other part is that the overlap, the co-occurrence of 
mental health problems among substance use disorders is 
very, very high, particularly major depressive disorder. 
In the field, we sort of have this artificial distinction between 
mental health disorders like depression, PTSD, bipolar 
disorder, schizophrenia, and substance use disorders, such 
as opioid use disorder, alcohol use disorder, tobacco use 
disorder. It’s a pretty artificial divide. It really shouldn’t exist. 
They’re all brain diseases. They’re all chronic illnesses. There’s 
a lot of genetic vulnerability overlap, and there’s a lot of 
behavioral overlap—and one of the behavioral aspects that 
overlaps across the spectrum is suicidality.
So, we have a spectrum of suicidality. We have patients that 
(A) are flirting with disaster in the first place. They’re using a 
substance that they will tell you, “I know it could kill me,” and 
(B) a lot of these people are suffering, tremendously. Their 
lives are chaotic. They have depression. They have trauma. 
And there’s despair. It may not be all the time, but many of 
them will say, “You know, if I had to go out using and sort of 
sleeping into my death? Not such a bad thing. There’s a lot of 
worse ways that I could die, especially with what’s happening 
in my life right now.” So that’s not quite suicidality, but it’s 
getting closer on the self-harm spectrum.
Then the other thing that we forget is that the way that 
substance users experience suicidality is quite different 
from the way that somebody with a melancholic, chronic, 
major depression experiences suicidality. The melancholic 
depressed patient can’t get out of bed, doesn’t want to brush 
their teeth, and is thinking about suicide as the only possible 
relief to this awful state that just goes on.
One of the reasons I like working with substance users is 
they’re full of life; very resilient people. They have incredible 
stories. They’ve lived through all sorts of things. Oftentimes, 
they’re lively and have a good sense of humor. The way they 
experience despair and suicidality is quite different.
It’s often brief, episodic. They could be having a great day, 
then something shifts. Sometimes it’s related to using a 
substance because they get more disinhibited about the 
despair side or prior suicidal thoughts that they’ve had. They 
can have these brief onsets of very deep despair and active 
suicidality that because they’re using lethal substances 
are even more dangerous. That’s suicidality. That’s not just 
because it looks different from a melancholic, depression 
suicidality. It’s still lethal suicidality.
So, they’ll say to you, “Most of the time, I don’t really wanna 
die. I — I have a lot to live for. But there are times when I really 
do wanna die.” And those are really the danger times.
 
Why do I think this is happening and contributing to the 
overdose epidemic? Two reasons. Two publications this year 
that really got my attention that people are not talking about. 
One was a longitudinally followed cohort, an 11-year follow-up 
of an Australian study of heroin users — 600+ people,  
a large cohort.
Of people who entered treatment, 42% of them had  
self-reported suicide attempts. We know that already.  
We know substance users have high rates of baseline suicide 
attempts. But when they followed them out even at year 11, 
the persistence of suicidality was tremendous: 10% with still 
active suicidal ideation, and about 4% actually maintained  
a plan.
Even though they were in treatment, and getting better in 
certain ways, suicidality persisted. We see that in our own 
clinics. We see that in practice. That’s the mental health 
component.
The other thing was that there was a national report put out 
this year that looked at overdose deaths with prescription 
opioids. It was a multi-center collection of poison center calls 
that looked from 2006 to 2013 at the overdose deaths related 
to prescription opioids. Seventy-five percent were called in 
with known suicidal intent. Why is nobody talking about this?
Then, if you looked at just those who are age 60 or older: 
86% suicidal intent. That says something really important.  
I feel like we’re missing this in the dialogue. I’m not saying 
that there aren’t unintentional overdose deaths. I’m just 
saying that we don’t want to simplify the problem as people 
getting prescribed too much pain medication, then they’re 
addicted, and now, as an addict, they have reckless behavior, 
and they accidentally overdose.
That’s not really the story here. We have a much richer story 
about people’s lives being tough; people having vulnerability; 
people having co-occurring mental health problems; and 
suicide as a real problem.
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You can also reflect on the fact that suicide rates in the 
United States continue to go up, and are particularly 
alarming among our youth. So, there’s something bigger 
that’s happening here. I think that it’s relevant for reducing 
stigma. I think it’s relevant for developing programs that have 
more comprehensive treatment and aspects that are going 
to address depression and suicide prevention. It’s not just 
looking at, “Let’s get you clean and sober.”
Then the other question that has come up a lot, particularly 
when people talk about changing the criminal justice system: 
What should we do for people who have been incarcerated, 
who have an opioid use disorder, and are now being released 
in the public and are at very high risk for relapse as well as 
overdose?
There’s a push to use just antagonist treatment, Vivitrol, and 
I don’t really have a problem with that, as long as it turns out 
that we can study it, and it’s effective.
Because there was a lot of interest in doing this, the question 
sort of generalized: why are we giving anybody agonist 
treatment? Why can’t we just treat everybody with the 
blocker — with Vivitrol? 
The reason for that is that there are a lot of people who just 
simply won’t respond to that. Not everybody will do well 
with an antagonist-based treatment like Vivitrol. There are 
a couple of problems with it. For the example of the person 
who’s been incarcerated, if they haven’t been exposed to 
opioids (which is another story—there is a lot of opioid use  
in the prisons), they don’t need to have a washout period. 
That’s straightforward. You can start them on naltrexone 
before they go. They can then continue to get their treatment.
However, for many people coming into treatment, they  
have to really go through a detoxification process, where the 
opioids wash out, so there has to be a significant amount of 
time, at least a week, before it’s safe to give them naltrexone.
And this week, where they’re just in opioid withdrawal, is a 
high dropout period. People don’t tolerate it well, and they 
just basically have trouble making it to that first dosing. So 
that’s one problem.
Another problem is that many people who get onto Vivitrol 
come in, they get their first injection, and then they disappear 
from treatment. Or, maybe they get two injections, and then 
they drop out. That’s a problem, too. We’re working on trying 
to improve retention in this treatment model.
It has been a problem because when they do drop out, 
they’ve lost their tolerance, and if they relapse, they’re now  
at a great risk for opioid overdose.
The other treatments, while there’s a downside to having 
activation at the opioid receptor, the upside is that it does 
preserve a little tolerance. They’re less likely to have an 
overdose fatality when they do overdose.
So, for the moment anyway, until we get better with all  
of this, we need all three medications.
Then, finally, what do families need in addition to 
intranasal naloxone rescue training? Which I’m so pleased 
Massachusetts has taken up very rapidly, and access keeps 
improving, so I’m not going to actually talk too much about 
that, because we’re really doing a good job with that.
I’m going to talk about the other aspects, though. In a 
nutshell, families are mostly suffering from anxiety of losing 
their loved one. They’re terrified. They know that at any 
moment, they could get the knock on the door or the phone 
call, telling them their loved one is dead.
Then, there’s all of the other problems of addiction that they 
suffer with, what I call active using behaviors, that don’t 
reflect the person’s character baseline, but is a symptom of 
being actively in the disease: lying, cheating, stealing, etc.
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So what families really benefit from are peer support groups. 
That means getting together with other families who are in 
similar situations to share support resources and information.
I think the peer support groups can be especially helpful if 
you have a licensed professional facilitating it, not necessarily 
directing it, but being there to answer questions that may 
come up, or offer resources when somebody has a question 
that nobody can answer.
Families need clinical treatment. The families that I see?  
They have high levels of insomnia, anxiety, horrible 
depression, despair, hopelessness, fear, and trauma. The 
trauma of watching somebody get well, thinking you’re out  
of the woods, and then all of a sudden, “Oh my God, are we 
here again? I don’t know if I can live through this again.”
They need clinical treatment. They need therapy supports. 
Sometimes, they need targeted treatment for their own 
mental health issues: getting to sleep, depression, etc.
They need help from the law enforcement world. I can tell 
you, a lot of patients that I’ve seen, their families will say,  
“You know, in the worst of this, I found needles, heroin, a 
supply. I went to my police station saying, ‘I don’t know what 
to do with this. Can you do something with this?” Basically, 
you know, they’re up against, “We really can’t take that, 
ma’am, and also, your child will have drug charges if we do 
something about it.”
So, we have to figure out some way that families can get 
some more and better support from law enforcement without 
being put in this really strange situation of, it doesn’t belong  
in my possession, but I’m not really sure what else I can do 
with it.
And then, you know, unintended pregnancy, unplanned 
pregnancy—there are very high rates of that among 
substance users for a variety of reasons. But when a 
substance-using woman becomes pregnant and makes a 
decision with their family that they want to keep the child,  
the way they are treated in our healthcare system is awful. 
Just awful. This extends to families, too.
So, I think that one of the places that we could immediately 
do a lot of good is to train our clinicians who work in prenatal 
and postnatal care how to be more understanding about 
what the disease of addiction is, how difficult it is to break. 
Essentially, deliver more effective, compassionate care, which 
is not only going to be good for the families and the woman, 
but also for the baby who is developing.
Medication access. These are things that the Division of 
Insurance can work on — medication access for everybody. 
For all three medications, having the choice, so that if you try 
one and you don’t respond to it, you can easily and rapidly be 
tried on another. And not have gaps in your treatment due  
to your requirements for pre-authorization, delays in being 
able to get something shipped to you, etc., etc.
Mental health care: I think I’ve already said enough  
about that, but if that’s not put into the treatment planning, 
you’re not likely to get the kind of outcome that you want.
Offering more levels of care: The gap between inpatient level 
of care and outpatient level of care is just too wide. We need 
day treatment. We need more residential treatment.
And then finally, toxicology services. Again, not for the point 
of policing patients, but they’re the only objective data. I 
call them my vital signs — our breathalyzer for alcohol use 
disorder, and urine toxicology or other toxicology for drug use 
disorders. These are our vital signs. They’re the only ones we 
have, really.
Yet, somehow, in our line of work, instead of having a 
technician who comes in and takes your blood pressure and 
your pulse and then collects some blood for routine tests, 
we’re told, “Oh no, no. You can’t have that. And we’re going  
to put a limit on the number of times that you can use this 
kind of assay to inform your clinical interventions.” That’s  
just dumb.
You know, effective care needs to have reasonable access to 
toxicological services. It would actually benefit from having 
more of a medical model of payment for somebody up front 
to do the weight, the blood pressure, the pulse, other vital 
signs, and wellness checks, which would be very helpful to 
providing comprehensive care.
This is chronic maintenance care. That’s the point. So, if those 
things are provided better for patients, families are also going 
to have a much easier time with it.
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Question anD answeR
audience:  You had mentioned the high-risk pregnancy 
[inaudible]. Have you seen children who are born from high-
risk pregnancies, the side effects that they suffer?
Dr. Connery:  In this case, we’re talking about opioid use 
disorders, so we’re talking about the awful event of neonatal 
abstinence syndrome, which is when you see  a baby who has 
been exposed in utero to opioids to a level of addiction, and 
are born in opioid withdrawal.
As I mentioned, opioid withdrawal is miserable. It’s an awful 
physical and anxiety depressive state. When you see these 
babies, it is actually very horrifying. I understand why people 
look at that and say, “How can we allow this to happen to 
these babies?”
But I ask the question, if we don’t treat women, then what? 
The babies are going to come anyway, right? But now, these 
babies will not have had any appropriate prenatal care. So 
they’ll have all the problems of addiction, including a mother 
who’s actively addicted and probably depressed, as well as 
all of the health problems of having not received a stitch of 
prenatal care and not having the opportunity of a planned 
delivery. This baby is going to have special requirements.  
We need to be ready for it. We need to plan for it.
So, the alternative just isn’t viable. I mean, leaving these 
babies to be born God-knows-where and without proper 
prenatal care and delivery planning; that’s not an answer.  
I don’t have the miracle answer, which I wish I did, which 
would be: Can we spare the babies from all of this?
But in reality, right now, the best we could do is really be 
compassionate, engaging these women who are pregnant in 
treatment that works, providing resources. If they can’t stop 
using even with treatment, residential treatment, protect 
them from the environment. Provide for them. Provide for the 
child. At least give them the opportunity to become  
good mothers.
They may not make it, but some do. And on the point of the 
post-delivery part, we thankfully have medical treatments 
that will stabilize these babies. You know, there are some 
people who were babies born to opioid-addicted women, who 
suffered through the neonatal abstinence syndrome, and are 
productive members of society; happy to be alive.
So, that’s my picture of it. It is an awful reality, but there’s a lot 
that we can do to mitigate that awful reality, and end up in a 
better place. 
audience:  You mentioned that [inaudible] users know that 
they’re—say heroin, for example—when they shoot up, 
they know they can potentially kill themselves? What are 
your thoughts on the effectiveness of Narcan? And while 
it’s keeping people alive, some of these [inaudible] users—
they’re starting to use it as a safety net. And do you think 
that’s starting to ruin that perception of, “Oh, well, I don’t 
have to worry about dying because I have a couple bags  
of this?”
Dr. Connery:  Okay. I’m glad you bring that up. So the 
question is, is the use of intranasal Narcan actually creating a 
safety net for opioid users whereby they think, “Well, if I have 
that handy or my friends have it handy, you know, I’m not 
gonna kill myself. So that gives me more freedom to use.” 
I have two answers to that. Actually, I have…
audience:  Or just maybe take away some of the danger.
Dr. Connery:  Yeah. I have three answers to that. Number one, 
if you’ve ever worked with an opioid addict, they don’t think 
that way when they’re using. None of that is going on in their 
head at all. They’re not rational. They’re not thinking about 
anything other than my brain receptors are screaming that it’s 
time to use, and I’ve got to use.
So that line of logic that seems like it would be expected 
from those of us who aren’t addicted to opioids, you have 
to understand, they’re not even thinking about that. That’s 
number one.
Number two, there’s no evidence that the use and 
dissemination of intranasal Naloxone has increased opioid 
use. The only evidence we have is that it’s done a damn good 
job of preventing people who would otherwise be dead from 
being dead. They’re still alive.
Number three, there is the very important question of, “What 
do we do with them once we’ve resuscitated them?” Because 
as I mentioned earlier, you give somebody intranasal Narcan, 
they don’t wake up and say, “Thank you for saving my life.” 
They wake up and they’re in the most miserable level of 
opioid withdrawal that you can imagine. And they wake up 
screaming, angry, get away from me. I mean, literally, they’re 
out of their minds. And the only thing on their mind is, I need 
to use again. Right? Because that’s what’s going to fix it. This 
is part of the brain illness aspect to it.
We’ve got AEDs in our malls. When we defibrillate somebody 
who has had a heart attack in the mall, what do we do? Do 
we say, “Oh, you don’t want treatment? Okay, good luck. 
Hope you have a good life. If you’re not dead in a month, 
maybe I’ll see you at the mall again.”
We don’t do that. If somebody gets defibrillated in public, 
they get treatment. Right away, they get treatment. Right? 
And if they say, “Oh, you know, no thanks. I don’t want 
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treatment,” people bend over backwards trying to say, “Are 
you nuts? You almost died there. You need treatment.” Right?
But somehow, we’ve had intranasal Naloxone for years, where 
people wake up and they’re angry, they want to use. A lot of 
times, they just get discharged and sent on their merry way. 
There’s a discrepancy there that’s just crazy.
I think that Governor Baker’s new mandate—that somebody 
within 24 hours gets a qualified professional evaluation for 
substance use disorder and offered appropriate access to 
treatment—is such a step in the right direction.
We may end up needing more than that, but that is just right 
on target, and I really applaud that. 
audience:  So, to me it sounds like when we’re talking about 
the spectrum of self-harm, there’s a group that, you know, is 
flirting with disaster in the sense that they are suicidal and 
there is medical treatment for that. But there’s also on the 
other end of the spectrum, risk-seeking individuals who, you 
know, might not wear their seatbelt. And then, you know, 
maybe this group is a potential group to target prevention, 
intervention as a [inaudible] for a drug use disorder? I was 
wondering if there’s any research that goes into that? Or 
is the dialogue surrounding this self-harm, but not quite 
classified as a medical need?
Dr. Connery:  There is. So, the question is, on the topic  
of self-harm and just risk-taking behavior in general, how 
can we use this for the purpose of prevention? Prevention of 
injury. Prevention of death. Prevention of addiction.
The dialogue is actually happening amongst the public health 
experts. There’s a group of them who have been pretty 
vocally advocating that we change the way we’re coding 
deaths.
The self-harm aspect: if we identify this as an accident, then 
our capacity to intervene in ways that will be effective for 
prevention is minimized, but if we identify this as behavior for 
which we can identify effective interventions for prevention, 
now we’re doing a lot of good.
One of the points that these public health experts make 
is that the burden of evidence on medical examiners to 
determine cause of death as intentional or suicide-related is 
very, very high.
So, if somebody hangs themselves; somebody puts a gun 
in their mouth; somebody puts a bag over their head; those 
are pretty obvious. They get coded suicides. Somebody does 
something less obvious like overdose on pills or drugs, and 
there’s a note there, “Dear loved ones, please forgive me,  
but I couldn’t take it anymore.” Okay, that’s suicide.
But in the many cases of overdose — whether it’s by the 
needle or by a bottle of pills, or a bunch of alcohol mixed with 
all of this — there’s no note. The only way that you would 
really be able to call it a suicide, according to our current 
coding, is if there was a sufficient investigation of that case 
that determined pre-existing mental health problems or 
suicidality. And enough evidence to piece it together and say, 
“Yes, probably this was in the self-harm suicide spectrum.”
So, the problem is that the deaths are getting captured, but 
not necessarily being categorized in the right bins. We’re 
probably undercounting suicides significantly. If we change 
the way that we’re coding these things to include deaths that 
are self-inflicted, or self-harm deaths, we can do a whole lot 
more on the public health prevention side around testing 
interventions that will effectively prevent this. I’m 100% 
behind that.
The other piece that I think is so important is that the 
dialogue is happening, and many people are now mobilizing 
to do something about this problem, but mental health is not 
really getting the play that it needs in this picture.
And, you know, some of the reasons for that may be people 
are afraid of how much it’s going to cost. Right? If we can 
cleanly separate this as an addiction problem, then let’s just 
get this supply of opioids out of the way and treat addiction: 
that seems like it’s going to cost less than dealing with all of 
the other chronic illnesses—trauma, depression, suicidality.
Treatment is costly. Treatment for mental health and 
substance use is not like many other medical treatments in 
the sense that it often requires multiple contacts per week 
as an outpatient. You might see a psychiatrist. You might see 
a therapist. You might go to group therapy. You’re going to 
peer support, like 12-step or Smart Recovery, multiple times 
a week.
This is hard on people, especially people with jobs or children 
that they’re raising. And, frankly, it’s part of what continues 
to fuel the stigma because you’re doing the treatment that’s 
prescribed. It’s very intensive. It’s what’s required to get 
recovered, but what does your boss think of that? Another 
medical absence? 
I mean, it’s different than even having to go into an office 
once a week and get your vital signs monitored and 
something checked. It’s much more intensive. So there is 
that perpetuation of stigma because it interferes with other 
conflicting responsibilities.
But the problem is, we don’t have a more efficient way to get 
people well yet. Hopefully, that will continue with research 
and development. But right now, this is what it takes to get 
people well.
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